PEGCETACOPLAN (APL -2) 
PROTOCOL APL2 -303 
A PHASE 3, MULTI -CENTER, RANDOMIZED, 
DOUBLE -MASKED, SHAM -CONTROLLED STUDY TO 
COMPARE THE EFFICACY AND SAFETY OF 
INTRAVITREAL PEGCETACOPLAN THERAPY WITH 
SHAM INJECTIONS IN PATIENTS WITH 
GEOGRAPHIC ATROPHY (GA) SECONDARY TO AGE -
RELATED MACULAR DEGENERATION (AMD)
US IN D No.: 124784
EudraCT No.:  2018-001436-22 
Phase: 3  
Version:  Amendment 5 
Date:  12 August 2020  
Confidentiality Statement
This document is confidential. It contains proprietary information of Apellis Pharmaceuticals, 
Inc. Any viewing or disclosure of such information that is not authorized in writing by Apellis Pharmaceuticals, Inc, is strictly prohibited. Such information may be used solely for the purpose of reviewing or performing this study. 
Apellis Pharmaceuticals, Inc Page 1 of 167 Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
INVESTIGATOR AGREEMENT  
Long Title :  A Phase 3, Multi-Center, Randomized, Double-
Masked, Sham-Controlled Study to Compare the 
Efficacy and Safety of Intravitreal Pegcetacoplan  
Therapy with Sham Injections in Patients with 
Geographic Atrophy (GA) Secondary to Age-
Related Macular Degeneration (AMD)  
Short  Title :  Derby  
Protocol Number , Version, and Date : APL2 -303 / Amendment 5 / 12 August 2020 
Study  Phase :  Phase 3  
Sponsor  Name  and Address :  Apellis Pharmaceuticals, Inc  
 100 5th Ave 
 Waltham, MA 02451 
 USA  
Investigational Test  Article:  Pegcetacoplan intravitreal injection ( also known as 
APL -2) 
US IND Number:  124784 
EudraCT Number:  2018-001436-22  
Indication Studied: Geographic atrophy secondary to age- related 
macular degeneration  
Investigator Agreement : I have read  the clinical  study described  herein , 
recognize its  confidentiality , and  agree to  conduct 
the described  trial in compliance with  Good Clinical 
Practice ( GCP ), the ethical  principles contained  
within  the Declaration  of Helsinki, this  protocol, 
and all applicable regulatory requirements .  
 
 Principal  Investigator :  
 Name: ____________________________________ 
  Signature : _________________________________  
 
 Date: ______/______/______ ( DD/MMM/ YYYY ) 
 
 
Apellis Pharmaceuticals, Inc
Page 2 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Updated the langua
ge within the Reporting Adverse Events section to be 
consistent with the new Apellis standard language.  Section  11.3 (previously 
Section  11.4)  
Updated the language within the Serious Adverse Events section to be 
consistent with the new Apellis standard language  Section  11.4 (previously 
Section  11.5)  
Removed the section on Unexpected Adverse Events or Unexpected 
Suspected Adverse Reactions as the information contained within it is 
now included in other revised sections to align with new Apellis standard 
language  previously Section  11.6 
Updated the language within the Pregnancy section to be consistent with the new Apellis standard language  Section  11.6 (previously 
Section  11.8)  
Removed APL -2 investigator’s brochure  from references  Section  15 
Updated Footnote s G and M  Appendix A, Appendix B , 
Appendix  C, Appendix D , and 
Appendix K  
Deleted follow -up visits from Schedules of Activities  Appendix B  and Appendix D  and 
Tables B and D of Appendix K  
Deleted pegcetacoplan and sham administration and post injection  
assessment from Visit  20 of the Schedule of Activities for monthly and 
every -other -month treatment groups  Month 13 to Month 30  Appendix B  and Appendix D  and 
Tables B and D of Appendix K  
 
 
Apellis Pharmaceuticals, Inc
Page 5 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
1. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS  
INVESTIGATOR AGREEMENT ...................................................................................................2  
SPONSOR INFORMATION  ..........................................................................................................3  
PROTOCOL AMENDMENT SUMMARY OF CHANGES  ..........................................................4  
1. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES  .................6  
2. SYNOPSIS  .................................................................................................................12  
3. ABBREVIATIONS  ....................................................................................................20  
4. INTRODUCTION  ......................................................................................................22  
4.1. Background .................................................................................................................22  
4.1.1.  Age-Related Macular Degeneration  ...........................................................................22  
4.1.2.  Pegcetacoplan  .............................................................................................................22  
4.1.3.  Nonclinical Data  .........................................................................................................23  
  
  
4.1.4.  Clinical Data  ...............................................................................................................26  
4.1.5.  Rationale  .....................................................................................................................27  
4.1.5.1.  Rationale for Pegcetacoplan for Treatment of Geographic Atrophy ..........................27  
4.1.6.  Dose Selection  ............................................................................................................27  
4.2. Risk/Benefit ................................................................................................................28  
5. STUDY OBJECTIVES  ..............................................................................................29  
5.1. Study Objectives .........................................................................................................29  
5.1.1.  Primary Objective  .......................................................................................................29  
5.1.2.  Key Secondary Objectives ..........................................................................................29  
5.1.3.  Secondary Objectives  .................................................................................................29  
5.1.4.  Safety Objectives  ........................................................................................................29  
5.1.5.  Exploratory Objectives ...............................................................................................30  
6. PATIENT POPULATION ..........................................................................................31  
6.1. Patient  Selection  .........................................................................................................31  
6.1.1.  Inclusion Criteria  ........................................................................................................31  
6.1.2.  Exclusion Criteria  .......................................................................................................32  
 
 
Apellis Pharmaceuticals, Inc
Page 6 of 167
Confidential
CCI
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
6.2. Wom en of Childbearin g Potential  ..............................................................................33  
6.3. Women of Non-Childbearing Potential ......................................................................33  
6.4. Approved Methods of Contraception .........................................................................33  
6.5. Discontinuation of Subjects ........................................................................................34  
7. TREATMENT OF SUBJECTS  ..................................................................................35  
7.1. Allocation to Treatment  ..............................................................................................35  
7.2. Masking and Minimization of Bias ............................................................................35  
7.2.1.  Unmasking ..................................................................................................................35  
7.3. Dosage and Administration ........................................................................................36  
7.3.1.  Dose Levels and Treatment Arms  ..............................................................................36  
7.3.2.  Treatment Administration  ...........................................................................................36  
7.3.3.  Drug Supplies .............................................................................................................37  
7.3.3.1.  Identity of Investigational Product .............................................................................37  
7.3.3.2.  Storage ........................................................................................................................37  
7.3.3.3.  Accountability  .............................................................................................................37  
7.3.4.  Intravitreal Pegcetacoplan Administration  .................................................................37  
7.4. Sham Injection Administration  ...................................................................................38  
7.5. Concomitant Therapies ...............................................................................................38  
7.5.1.  Treatment of New Exudation Related to Active Choroidal 
Neovascularization in the Study Eye and/or Fellow Eye ...........................................38  
7.5.2.  Prohibited Therapies ...................................................................................................39  
7.5.3.  Endophthalmitis Treatment ........................................................................................39  
8. STUDY PROCEDURES  ............................................................................................40  
8.1. Study Visit Schedule ...................................................................................................41  
8.1.1.  Screening Period —Within 28 Days Prior to Randomization/Treatment (Day 
–28 to Day –1) ............................................................................................................41  
8.1.1.1.  Visit 1—All Subjects  ..................................................................................................41  
8.1.2.  Randomization/Initial Treatment—Day  1—Within 28 Days of Screening ...............41  
8.1.2.1.  Visit 2—All Groups ....................................................................................................41  
8.1.3.  PK and Complement Sample- Day  7 (Select Sites)  ....................................................42  
8.1.3.1.  Visit 2A—All Groups (Select Sites) ...........................................................................42  
8.1.4.  Treatment Phase—24 Months ....................................................................................42  
8.1.4.1.  Months 1-12 ................................................................................................................42  
 
 
Apellis Pharmaceuticals, Inc
Page 7 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
8.1.4.2.  Months 13-24 ..............................................................................................................43  
8.1.5.  Early Termination Visit ..............................................................................................44  
8.1.6.  Unscheduled Visits .....................................................................................................44  
9. ASSESSMENTS .........................................................................................................45  
9.1. Informed Consent .......................................................................................................45  
9.2. Demographic Information/Medical/Surgical History  .................................................45  
9.3. Ocular History/Ocular Procedures  ..............................................................................45  
9.4. Vital Signs  ..................................................................................................................45  
9.5. Physical Examination  .................................................................................................45  
9.6. Laboratory Analysis of Blood and Urine ....................................................................45  
9.7. Genotyping Samples ...................................................................................................46  
9.8. Urine Pregnancy Test  .................................................................................................46  
9.9. Patient -Reported Outcomes  ........................................................................................47  
9.9.1.  The National Eye Institute Visual Functioning Questionnaire 25- Item 
Version  ........................................................................................................................47  
9.9.2.  The Functional Reading Independence Index ............................................................47  
9.10.  Best Corrected Visual Acuity and Low Luminance Best Corrected Visual 
Acuity  .........................................................................................................................47  
9.11.  Minnesota Low-Vision Reading Test or Radner Reading Charts (in Select Countries) ...................................................................................................................48
 
9.12.  Home -Based Functional Digital Applications (Optional, in Select Sites)  .................48  
9.13.  Complete Ophthalmic Exam .......................................................................................48  
9.14.  Ocular Imaging  ...........................................................................................................48  
9.15.  Postinjection Assessment............................................................................................49  
9.16.  Blood Volume for Study Assessments .......................................................................50  
9.17.  Samples for Clinical Repository (Optional, Select Site s) ...........................................50  
9.17.1.  Approval by the Institutional Review Board or Ethics Committee ............................51  
9.17.2.  Sample Collection  .......................................................................................................51  
9.17.3.  Confidentiality and Data Ownership ..........................................................................51  
9.17.4.  Consent to Participate in the Clinical Repository  .......................................................52  
9.17.5.  Withdrawal from the Clinical Repository  ...................................................................52  
9.17.6.  Monitoring and Oversight...........................................................................................52  
10. SAFETY EVALUATIONS  ........................................................................................53  
 
 
Apellis Pharmaceuticals, Inc
Page 8 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
10.1.  Data Monitoring Committee  .......................................................................................53  
11. ADVERSE EVENTS ..................................................................................................54  
11.1.  Definition  ....................................................................................................................54  
11.2.  Recording Adverse Events .........................................................................................54  
11.3.  Reporting Adverse Events ..........................................................................................55  
11.3.1.  Relationship of Events to Study Treatment ................................................................55  
11.3.2.  Severity of Events .......................................................................................................56  
11.4.  Serious Adverse Events ..............................................................................................56  
11.5.  Treatment and Follow-up of Adverse Events .............................................................56  
11.6.  Pregnancy  ...................................................................................................................57  
11.7.  Disease Progression  ....................................................................................................57  
11.8.  Withdrawal  .................................................................................................................57  
12. DATA MANAGEMENT AND STATISTICAL CONSIDERATIONS  ....................58  
12.1.  Data Collection  ...........................................................................................................58  
12.2.  Clinic al Data Management  .........................................................................................58  
12.3.  Statistical Analysis Process  ........................................................................................58  
12.4.  Planned Interim Analysis and Data Safety Monitoring Committee ...........................58  
12.5.  Sample Size Calculation and Power Considerations  ..................................................59  
12.6.  Statistical Analysis Sets  ..............................................................................................59  
12.7.  Efficacy Analyses  .......................................................................................................60  
12.7.1.  Primary Efficacy Analysis  ..........................................................................................60  
12.7.2.  Secondary Efficacy Analysis ......................................................................................61  
12.7.3.  Exploratory Efficacy Analysis ....................................................................................62  
12.8.  Safety Analyses  ..........................................................................................................62  
12.8.1.  Anti-Therapeutic Antibodies ......................................................................................63  
12.8.2.  Death  ...........................................................................................................................63  
12.8.3.  Ocular Assessments  ....................................................................................................63  
12.9.  Pharmacokinetic Analyses  ..........................................................................................63  
12.10.  Handling of Missing Data ...........................................................................................63  
12.11.  Visit Windows  ............................................................................................................63  
13. ETHICS  ......................................................................................................................64  
13.1.  Ethical Conduct of the Study ......................................................................................64  
13.2.  Institutional Review Board/Ethic Committee  .............................................................64  
Apellis Pharmaceuticals, Inc
Page 9 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
13.3.  Subject Information and Consent ...............................................................................64  
14. ADMINISTRATIVE CONSIDERATIONS  ..............................................................65  
14.1.  Direct Access to Source Data/Documents  ..................................................................65  
14.2.  Quality Control and Quality Assurance ......................................................................65  
14.3.  Monitoring ..................................................................................................................65  
14.4.  Data Handling and Record Keeping ...........................................................................65  
14.5.  Protocol Amendments ................................................................................................66  
14.6.  Report Format .............................................................................................................66  
14.7.  Finance and Insurance  ................................................................................................66  
14.8.  Publication Policy  .......................................................................................................66  
14.9.  ClinicalTrials .gov .......................................................................................................67  
14.10.  Termination of Study ..................................................................................................67  
15. REFERENCES  ...........................................................................................................68  
16. APPENDICES  ............................................................................................................70  
APPENDIX A: VISIT SCHEDULE —Monthly Group—Screening, Day  1 Through 
Month 12 .....................................................................................................................70  
APPENDIX B: VISIT SCHEDULE —Monthly Group—Month 13 to Month 24 ........................74  
APPENDIX C: VISIT SCHEDULE —Every -Other -Month Group—Screening, Day 1 
Through Month 12 ......................................................................................................77  
APPENDIX D: VISIT SCHEDULE —Every -Other -Month Group—Month 13 to Month 
24 ................................................................................................................................81  
APPENDIX E: NATIONAL EYE INSTITUTE VISUAL FUNCTIONING 
QUESTIONNAIRE 25 -ITEM VERSION  ..................................................................84  
APPENDIX F: FUNCTIONAL READING INDEPENDENCE INDEX  ...................................101  
APPENDIX G: MINNESOTA LOW -VISION READING TEST AND RADNER 
READING CARDS  ..................................................................................................102  
APPENDIX H: GRADING SCALE FOR ASSESSMENT OF ANTERIOR CHAMBER 
FLARE OR CELLS  ..................................................................................................103  
APPENDIX I: GRADING SC ALE FOR ASSESSMENT OF VITREOUS CELLS  ..................104  
APPENDIX J: AMENDMENT HISTORY  .................................................................................105  
APPENDIX K: PROTOCOL CHANGES TO BE FOLLOWED DURING COVID-19 
RESTRICTIONS  ......................................................................................................117 
 
 
 
Apellis Pharmaceuticals, Inc
Page 10 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
LIST OF TABLES 
Table 1: Treatment Arms With Approximate Number of Subjects ...............................................36  
Table 2:  Laboratory Sampling and Analysis .................................................................................46  
Table 3: Total Study Blood Volume ..............................................................................................50  
Table 4: Power to Detect a Difference Among 3 Groups With an Equal Size of 
200 Subjects  ................................................................................................................59  
LIST OF FIGURES  
Figure 1: Study Schema .................................................................................................................40  
Apellis Pharmaceuticals, Inc
Page 11 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
2. SYNOPSIS  
Study Title  
A Phase 3, Multi -Center, Randomized, Double -Masked, Sham -Controlled Study to Compare the Efficacy and Safety 
of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to 
Age-Related Macular Degeneration (AMD)  
Protocol Number, Version , and  Date  
APL2 -303/ Amendment 5 / 12 August 2020  
Investigational Product, Dose , and Route of Administration  
• Pegcetacoplan  (also known as APL -2)15 mg/0.1 mL  
• Intravitreal (IVT) Injection  
Study Arms  
Arm  Abbreviation  Randomization  
Pegcetacoplan 1 5 mg/0.1 mL monthly for 24 months  PM 2 
Pegcetacoplan 1 5 mg/0.1 mL every  other  month for 24 months  PEOM  2 
Sham monthly for 24 months  SM 1 
Sham every  other  month for 24 months  SEOM  1 
Study Phase and Type  
Phase 3, multicenter, randomized, double -masked, sham -injection controlled . 
Number of Subjects and Sites  
• Approximately 60 0 subject s 
• Approximately 100 sites  
Objectives  
Primary   
To evaluate the efficacy of pegcetacopl an compared to sham injection in patients with geographic atrophy (GA) 
secondary to age-related macular degeneration (AMD) assessed by change in the total area of GA lesions from 
baseline as measured by fundus autofluorescence ( FAF). 
Key Secondary  
To evaluate the efficacy of pegcetacoplan compared to sham  injection in patients with GA secondary to AMD with 
respect to:  
• Monocular maximum reading speed (study eye), as assessed by Minnesota Low -Vision Reading Test 
(MNREAD) or Radner Reading Charts (in select countries)  
• Functional Reading Independence Index score  
• Normal luminance best  corrected visual acuity score in the study eye  
Apellis Pharmaceuticals, Inc
Page 12 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Secondary  
• To evaluate the efficacy of pegcetacoplan compared to sham  injection in patients with GA secondary 
to AMD with respect to: 
o Low luminance best corrected visual acuity score in the study eye  
o Low luminance deficit in the study eye  
o Total area of GA lesion(s) in the study eye  
o Monocular critical print size (study eye), as assessed by MNREAD or  Radner Reading Charts 
(in select countries)  
o National Eye Institute Visual Functioning Questionnaire 25 -Item Version (NEI VFQ -25) 
distance activity subscale score (in select countries)  
• To evaluate the pharmacokinetics  of pegcetacoplan as assessed by systemic plasma concentration of 
pegcetacoplan (in select sites) 
Safety  
• To evaluate the safety and tolerability of pegcetacoplan compared to sham injection in patients with 
GA secondary to AMD as indicated by:  
o Incidence and  severity of ocular and systemic tre atment -emergent adverse events  
o Incidence of anti -therapeutic  antibodies directed against pegcetacoplan  
o Incidence of new active choroidal neovascularization ( CNV ) in the study eye  
Exploratory  
• To evaluate the efficacy of p egcetacoplan compared to sham  injection in patients with GA secondary 
to AMD as indicated by:  
o NEI VFQ- 25 composite score  
o NEI VFQ- 25 near activity subscale score (in select countries)  
o Comparison between study eye and fellow eye in change in GA lesion size  
o To evaluate the maximum binocular reading speed as assessed by MNREAD or Radner 
Reading Charts (in select countries)  
o To evaluate the binocular critical print size as assessed by MNREAD or Radner Reading 
Charts (in select countries)  
• To evaluate the relatio nship between genetic polymorphisms associated with AMD with GA 
progression and response to pegcetacoplan  
• To evaluate the incidence of new onset of subclinical CNV in the study eye  
• To assess sensitivity and specificity of a digital reading speed application to detect disease 
progression/ regression (optional, select sites)  
• To assess sensitivity and specificity of a digital visual function application to detect disease progression/ regression (optional, select sites)  
Apellis Pharmaceuticals, Inc
Page 13 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Inclusion Crite
ria 
The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with the worst visual 
acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right 
eye will be selected as the study ey e. 
Ocular - specific inclusion criteria apply to the study eye  only, unless otherwise specified.  
1. Age ≥6 0 year s. 
2. Normal luminance best corrected visual acuity of 24 letters or better using Early Treatment Diabetic 
Retinopathy Study (ETDRS) charts (approximately 20/320 Snellen equivalent).  
3. Clinical diagnosis of GA of the macula secondary to AMD as determined by the investigator and confirmed 
by the reading center . 
4. The GA lesion must meet the following criteria as determined by the central reading ce nter ’s assessment 
of FAF imaging at screening:  
a. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas respectively)  
b. If GA is multifocal, at least 1 focal lesion must be ≥1.25  mm2 (0.5 disk areas ), with the overall 
aggregate area of GA as specified ab ove in 4a.  
c. The entire GA lesion must be completely visualized on the macula centered image and must be able to 
be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.  
d. Presence of any pattern of hyperautofluorescence in the jun ctional zone of GA. Absence of 
hyperautofluorescence (ie, pattern  = none) is exclusionary.1 
5. Adequate clarity of ocular media, adequate pupillary di lation, and fixation to permit the collection of good 
quality images as determined by the investigator.  
6. Female subjects must be:  
a. Women of non- childbearing potential, or  
b. Women of childbearing potential with a negative serum pregnancy test at screening and must agree to 
use protocol -defined methods of contraception for the duration of the study and refrain from 
breastfeeding for the duration of the study.  
7. Males with female partners of child bearing  potential must agree to use protocol -defined methods of 
contr aception and agree to refrain from donating sperm for the duration of the study.  
8. Willing and able to give informed consent and to comply with the study procedures and assessments.  
Exclusion Criteria  
Ocular specific exclusion criteria apply to the study eye  only, unless otherwise specified.  
1. GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy, or  toxic 
maculopathies like plaquenil maculopathy in either eye.  
2. Spherical  equivalent of the refractive error demonstrating >6  diopters of myopia or an axial length 
>26 mm. 
3. Any history or active CNV, associated with AMD or any other cause, including any evidence of retinal 
pigment epithelium rips or evidence of neovascularizatio n anywhere based on spectral domain optical 
coherence tomography  imaging and/or fluorescein angiography as assessed by the reading center . 
4. Presence of an active ocular disease that in the opinion of the investigator compromises or confounds 
visual function, including but not limited to, uveitis, other macular diseases (eg, clinically significant 
Apellis Pharmaceuticals, Inc
Page 14 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
epiretinal mem
brane, full thickness macular hole or uncontrolled glaucoma/ocular hypertension). Benign 
conditions in the opinion of the investigator such as peripheral retina dystrophy are not exclusionary.  
5. Intraocular surgery (including lens replacement surgery) within 3  months prior to randomization.   
6. History of laser therapy in the macular region.  
7. Aphakia or absence of the posterior capsule. Note: Yttrium  aluminum garnet laser posterior capsulotomy 
for posterior capsule opacification done at least 60 days prior to screening is not exclusionary.  
8. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention 
during the study period or, in the opinion of the investigator, could compromise visual function during the 
study period.  
9. Any contraindication to IVT injection  including current ocular or periocular infection.  
10. History of prior IVT  injection.  
11. Prior participation in another interventional clinical study for IVT  therapies in either eye (including 
subjects receiving sham).  
12. Prior participation in another interventional clinical study for GA  in either eye including investigational 
oral medication and placebo.  
13. Participation in any systemic experimental treatment or a ny other systemic investigational new drug 
within 6 week s or 5 half -lives of the active ingredient (whichever is longer) prior to the start of study 
treatment. Note: clinical trials solely involving observation, over- the-counter vitamins, supplements, or 
diets are not exclusionary.  
14. Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow -up over 
the 24 -month treatment period unlikely, or would make the subject an unsafe study candidate.  
15. Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the opinion of the 
investigator is clinically significant and not suitable for study participation.  
16. Known hypersensitivity to fluorescein sodium for injection or hypersensitivity to pegcetacoplan or any of 
the excipients in pegcetacoplan solution.  
Study Design  
This is a 24 -month, Phase 3, multicenter, randomized, double -masked, sham -injection controlled study to assess the 
efficacy and safety of multiple IVT injections of pegcetacoplan in subjects with  GA secondary to AMD.  
The study will randomize approximately 600 subject s across approximately 100 multinational sites. Subjects will be 
screened within 28 days before receiving pegcetacoplan or sham injection. Upon entry into the study, subjects will 
be assigned a screening number. Subjects who meet all inclusion and none of the exclusion criteria will return to the 
clinic for randomization and treatment on Visit 2 ( Day 1). At this visit, subjects will be randomized 2:2:1:1 to 
receive pegcetacoplan monthly (PM) , pegcetacoplan  every other month (PEOM), sham injection monthly (SM) , or 
sham  injection every other month (SEOM), respectively. Randomization will be stratified according to GA lesion 
area at screening (<7.5 mm2; ≥7.5 mm2), and presence of CNV in the fellow eye.  
All subjects will be assessed monthly during the first 12 months regardless of treatment regimen. From Month 12 to Month 24, subjects will follow the outlined visit schedule ( Appendix A  to Appendix D) based on treatment 
assignment (ie, subjects in the monthly groups will be assessed monthly while subjects in the every -other -month 
[EOM] group will be assessed EOM ). The last visit in the study will be at Month 24, approximately 30  days 
Apellis Pharmaceuticals, Inc
Page 15 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
(monthly treat
ment group) or 60 days (EOM treatment group) after the last visit at which investigational product is 
administered. At the end of the 24- month study period, subjects will have the option to enroll into a separate open -
label study.  
Subjects who discontinue study treatment, can continue participation in the study and should be encouraged to return 
to the clinical site for as many follow -up visits as they can (with the exception of pegcetacoplan/sham 
administration). Subjects who wish to fully withdraw from the study before Month 24, should be encourage d to 
complete the early termination visit. 
Endpoints and Statistical Analysis: 
Endpoints  
Primary Efficacy Endpoint  
• Change from baseline to Month 12 in total area of GA lesion(s) in the study eye (in mm2) based on FAF.  
Key Secondary Efficacy Endpoints  
• Change from baseline in monocular maximum reading speed (study eye), as assessed by MNREAD or 
Radner Reading Charts at Month 24 (in select countries)  
• Change from baseline in Functional Reading Independence  Index score, at Month 24.  
• Change from baseline in normal luminance best  corrected visual acuity score at Month 24 as assessed by 
ETDRS chart.  
Secondary Efficacy Endpoints  
• Change from baseline in low luminance best corrected visual acuity score at Month 12 and Month 24 as 
assessed by ETDRS chart.  
• Change from baseline in low luminance deficit  at Month 12 and Month 24.  
• Change from baseline at each planned assessment in the total area of GA lesion(s) in the study eye (in mm
2) as assessed by FAF.  
• Change from baseline in monocular critical print size (study eye), as assessed by MNREAD or Radner 
Reading Charts, at Month 12 and Month 24 (in select countries).  
• Change from baseline in the NEI  VFQ -25 distance activity subscale score at Month 12 and Month 24 (in 
select sites).  
• Systemic plasma concentration of pegcetacoplan over time (in select sites).  
Exploratory Endpoints   
• Change from baseline in NEI VFQ -25 composite score at Month 12 and Month 24.  
• Change from baseline in NEI VFQ -25 near activity subscale score at Month 12 and Month  24 (in select 
countries).  
• Comparison between study eye and fellow eye in change in GA lesion size from baseline to Month 12 and Month 24.  
• Binocular maximum reading speed as assessed by MNREAD  or Radner Reading Charts over time (in select 
countries).  
Apellis Pharmaceuticals, Inc
Page 16 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
• Binocular crit
ical print size as assessed by MNREAD or Radner Reading Charts over time (in select 
countries).  
• Relationship between genetic polymorphisms associated with AMD with GA progression and response to 
pegcetacoplan.  
• Incidence of new onset of subclinical CNV in the study eye.  
• Assess sensitivity and specificity of a digital reading speed application to detect disease progression/ regression (optional, s elect sites).  
• Assess sensitivity and specificity of a digital visual function application to detect disease progression/ regression (optional, select sites).  
Safety Endpoints  
• Incidence and severity of ocular and systemic treatment -emergent adverse events.  
• Incidence of anti -therapeutic  antibodies directed against pegcetacoplan.  
• Incidence of new active CNV in the study eye.  
Analysis of Primary Efficacy Endpoint  
The primary efficacy endpoint is the change from baseline to Month 12 in the total area of GA lesion(s) in eyes injected with pegcetacoplan, either PM or PEOM, or sham injections. GA lesion area (mm
2) as measured by a 
quantified central reading center  based on FAF images. The primary analysis will be the comparison of 
pegcetacoplan, either PM or PEOM versus the combined 2 sham arms (the 2 sham arms will be combined into a 
single ‘control’ group).  
The null and alternative hypotheses for the primary efficacy analysis are:  
H0: µS = µ PM   vs  H A:  µ S ≠ µ PM, and  
H0: µS = µ PEOM vs  H A:  µ S ≠ µ PEOM  
Note: Here µ indicates each group’s respective mean change from baseline to Month 12 in GA lesion area for the 
comparison of the primary endpoint.  
A mixed effect model for longitudinal data will be used to analyze the change from baseline in GA lesion area. The 
model will include treatment, and presence of CNV in the fellow eye as fixed effects; baseline GA lesion area (at screening), time (in months) as a factor; as well as the time  × treatment interaction term . All available data up to 
12 months will be inc luded in the model for the primary analysis. The mean change from baseline to 12 months will 
be estimated from the model (ie, LS mean) and compared between each of the pegcetacoplan arms to the sham control. For other time point of interest, LS mean change  from baseline will be estimated and compared between 
treatments. Unstructured variance covariance will be used,  
For the analysis of final study data, a similar model including data up to 24 months will be used and LS means at time points  of interest will be estimated and compared between treatment.  
This study is expected to have an approximately 5 data monitoring committee  data reviews. Allocating an alpha 
level of 0.0001 for each data monitoring committee data review, the alpha level remains for the efficacy analysis at 
0.0495 to maintain an overall study alpha of 0.05.  
Apellis Pharmaceuticals, Inc
Page 17 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
The hypothesis te
sting strategy for the primary and secondary efficacy endpoints will be based on the Gate -keeping 
multiple testing procedures controlling for the study wide type I error st rongly at 2- sided 0.0495 as follows:  
Step 1. The mean GA lesion growth at 12 months will be compared between the PM group and the Control at 
the α level of 0.0495. If the null hypotheses of no difference between groups in this step is rejected, the testing proceeds to Step 2  and Step 3 . If it’s not rejected, the testing procedure stops at this step.  
Step 2. The mean GA lesion growth at 12 months will be compared between the PEOM group and the Control at the α1 level. If the null hypotheses of no difference between groups in this step is rejected, the α1 level will 
be passed down to Step 3 . The actual value of  α1 will be specified in the SAP and it will be defined to ensure 
an adequate power of at least 80% for the comparison in this step.  
Step 3. The mean GA lesion growth at 24 months will be compared between the PM group and the Control at 
the α level of 0.0495  if the null hypotheses are rejected at both Step 1  and Step 2 ; or at the α level of  
(0.0495 – α1) if Step 2  testing does not reject the null hypothesis. If the null hypothesis at this step is rejected, 
the α level used at this step will be passed down to the next step of testing. If it’s not rejected, the testing 
procedure stops at this step.  
Step 4. The prioritization and alpha allocation for the remaining secondary endpoints will be specified in the 
SAP.  
The following sensitivity and supportive analyses will be performed to evaluate the robustness of the results from the primary analysis method:  
• Analyses will be repeated using the modified  intent -to-treat and per-protocol sets  
• Primary and secondary endpoints will also be summarized with no pooling of the 2 sham arms. The comparison for pegcetacoplan and sham injection within each dose regimen (i e, PM vs SM and PEOM vs 
SEOM) will be conducted  
• Multiple imputation methods and other sensitivity analyses will be explored,  and details will be provided in 
the SAP 
Analysis for Key Secondary and Secondary Endpoint(s)  
The key secondary and secondary endpoints will be analyzed in the same fashion as the primary endpoint using mixed effect model. The binary secondary endpoints will be analyzed using Cochran -Mantel - Haenszel test stratified 
by the randomization stratification factors. Hypothesis testing for 3 key secondary endpoints will be performed in 
the order specified. The SAP will provide more details on multiplicity adjustment and the approach for alpha spendi ng among the endpoints.   
Sample Size Justification 
Subjects will be randomized in a 2:2:1:1 ratio to receive treatment with PM, PEOM , SM , or SEOM . The annual 
growth rate in GA lesion area is expected to have a mean of 1.47, 1.70 and 2.1 3 mm
2/year for PM , PEOM,  and 
sham -pooled groups, respectively, as estimated from the results of a Phase 2 trial for pegcetacoplan. The standard 
deviation of the lesion growth is estimated to be 1.50 mm2 based on the same Phase 2 trial data or 1.2 5 mm2 based 
on natural history data.26 With a sample size of 20 0 subject s in each group (ie, a total enrollment of 600 subject s) 
and the observed annual growth rate in GA lesion area f rom Phase  2 trial for pegcetacoplan, the study will have 
99.2% power to show the difference between PM and sham  group and 81.5% power to show the difference between 
PEOM and sham  group using the common standard deviation of 1. 5 mm2 and two -sided alpha of 0.05. The 
approximation is calculated using PROC POWER one -way analysis of variance, SAS 9.4. The study power is likely 
larger when utilizing the longitudinal data to model the primary endpoint. The actual study power may also vary 
Apellis Pharmaceuticals, Inc
Page 18 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
based on the distri
bution of the stratification factors (ie , lesion area at screening, presence of CNV in fellow eye), 
and site enrollment.  
Apellis Pharmaceuticals, Inc
Page 19 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
3. ABBREVIATIONS  
Abbreviation  Term  
AE adverse event  
AMD age-related macular degeneration  
CH50  classical pathway of complement functional test 
CNV  choroidal neovascularization 
Cmax Maximum concentration occurring at T max 
CRF (eCRF)  case report form  (electronic CRF) (used  interchangeably) 
DMC  data monitoring committee  
EOM  every other month 
ETDRS Early Treatment Diabetic Retinopathy Study 
FAF fundus autofluorescence 
FFA/FA  fundus fluorescein angiography or fluorescein angiography 
FRI Functional Reading Independence Index 
GA geographic atrophy 
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice 
IB investigator’s brochure 
ICF informed consent form  
ICH International Council for Harmonisation 
IEC independent ethics committee  
IOP intraocular  pressure  
IP investigational product 
IRB institutional review board  
ITT intent- to-treat 
IV intravenous 
IVT intravitreal 
LL-BCVA  low luminance best corrected visual acuity  
MedDRA  Medical Dictionary for Regulatory Activities 
Apellis Pharmaceuticals, Inc
Page 20 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
MNREAD Minnesota Low -Vision Reading Test  
MOP  manual of procedures 
NEI VFQ -25 National Eye Institute Visual Functioning Questionnaire 25- Item Version  
NIR near infrared reflectance  
NOEL  no-observable- effect level  
NL-BCVA  normal luminance best  corrected visual acuity 
OCT  optical coherence tomography 
OCT -A optical coherence tomography angiography 
PEG  polyethylene glycol 
PEG40  polyethylene glycol (40- kDa nominal molecular weight)  
PEOM  pegcetacoplan every  other month  
PI principal investigator  
PK pharmacokinetics 
PM pegcetacoplan monthly 
PP per-protocol  
RPE retinal pigment epithelium  
SAE  serious adverse event  
SC subcutaneous 
SC5b -9 soluble terminal complement complex (ie, soluble analog of membrane attack 
complex ) 
SD-OCT  spectral domain optical coherence tomography 
SEOM  sham every  other  month  
SM sham monthly  
TEAE treatment -emergent adverse event  
Tmax time of maximum observed concentration sampled during a dosing interval 
t1/2 terminal elimination half -life 
VEGF  vascular endothelial growth factor 
WOCBP  women of childbearing potential 
  
Apellis Pharmaceuticals, Inc
Page 21 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
4. INTRODUCTION 
4.1. Background  
This study is being conducted as part of a series of studies for the clinical development of 
pegcetacoplan  for advanced age-related macular degeneration (AMD) (neovascular AMD and 
geographic atrophy [GA]). The trial will be conducted in compliance with this protocol, Good Clinical Practice (GCP), and applicable regulatory requirements . The subject population will 
comprise adult male and female subjects with GA secondary to AMD. 
4.1.1. Age-Related Macular Degeneration  
Age-related  macul ar de generation  is the l eading cause of severe vision loss in people over the age 
of 65 in the United  States  and other We stern  countries.
2  In the United States, about 1.75 million 
people have the advanced forms of AMD.3  The early signs of AMD (drusen and pigmentary 
changes) are common in individuals over age 65 and precede the late stage forms, which are visually devastating. The late stage forms of AMD are classified into either macular 
neovascularization (neovascular, wet, or exudative AMD) or GA. 
Geographic atrophy is a disease characterized by thinning and loss of the retinal pigment 
epithelium (RPE) and concurrent atrophy of photoreceptors and choriocap illaris.
4,5,6  Clinically, 
GA is characterized by gradually expanding atrophy leaving islands of dead retinal cells in the 
back of the eye. Although GA can result in significant visual function deficits in reading, night 
vision, and dark adaptation, and produce dense, irreversible scotomas in the visual field, the initial decline in visual acuity  may be relatively limited if the fovea is spared. When the fovea is 
involved, GA quickly causes blindness.  
Genetic susceptibility has become increasingly recognized as a risk factor and important 
contributor to AMD. More than 19 genetic polymorphisms have been demonstrated to influence 
AMD risk, with as many as 5 of these encoded by genes that modulate the complement system. 
Inflammatory processes, especially those mediated by complement are thought to play a key role in AMD.
5 It is thought that these may contribute to loss of choriocapillaris, photoreceptors, and 
RPE cells .  
GA is responsible for approximately 20% of all cases of legal blindness in North America ( ie, 
best corrected visual acuity  20/200 or worse) with increasing incidence and prevalence owing to 
a higher life expectancy.4  While there is treatment for exudative AMD with anti–vascular 
endothelial growth factor ( VEGF ) therapies, no approved therapy exists for GA which is usually 
bilateral and relentlessly progressive. It represents a significant unmet need as it leads to significant visual impairment and affects more than 5 million people worldwide .
13 
An overview of available information regarding pegcetacoplan  follows below. Further details 
can be found in the pegcetacoplan  investigator’s brochure  (IB).1 
4.1.2. Pegcetacoplan 
Pegcetacoplan  is a PEGylated cyclic peptide inhibitor of complement C3 . Pegcetacoplan  is 
formed by 2 identical pentadecapeptides (combining a bioactive cyclic tridecapeptide  
C3–inhibiting moiety and a 2-amino acid linker) covalently coupled to each end of a linear 
Apellis Pharmaceuticals, Inc
Page 22 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
40-kDa polyethylene glycol (PEG) chain (PEG40). There are 2 peptide moieties per molecule of 
pegcetacoplan . 
The peptide portion of the drug binds to complement C3 and is a broad inhibitor of the 
complement cascade, a biological process that is part of innate immunity and is involved in 
multiple inflammatory processes. The PEGylation of the mole cule imparts slower clearance from 
the vitreous humor following administration.  
Pegcetacoplan  intravitreal (IVT) injection  15 mg/0.1 mL will be provided as a 150 mg /mL sterile 
solution of pegcetacoplan  in stoppered glass vials. Pegcetacoplan  is a sterile,  isotonic solution in 
acetate-buffer, pH 5.0, containing trehalose. The drug product is packaged in 2R clear Type I 
glass vials with 13 -mm FluroTec -coated chlorobutyl grey stoppers and sealed with 13- mm 
aluminum/polypropylene flip-off type seals.  
4.1.3. Nonclinical Data 
This section is intended to briefly summarize information on the safety, tolerability , and 
pharmacokinetics ( PK) of IVT , intravenous (IV), and subcutaneous ( SC) injections of 
pegcetacoplan . For complete and detailed information, refer to the IB. 
As pegcetacoplan  is only pharmacologically active in primates, the pivotal IVT toxicological 
studies have been conducted in cynomolgus monkeys. The safety and tolerability of 
IVT-administered pegcetacoplan has been assessed in a Good Laboratory Practice ( GLP )–
compliant pivotal chronic (9-month) repeat-dose study in cynomolgus monkeys. In addition, 
2 GLP -compliant 2 -month ocular bridging studies (the first comparing drug substance from 
2 different contract manufacturing organizations, the second assessing the safety and tolerability 
profiles of 3 different formulations to support the Phase 3 clinical study) have been conducted, in 
cynomolgus monkeys as well. Pegcetacoplan  was observed to be minimally immunogenic in the 
9-month study as evidenced by a lack of circulating antibodies in the majority of monkeys studied. The no-observa ble-effect level ( NOEL ) for chronic (9 -month) IVT dosing was 
concluded to be >24.8 mg/eye. The results of this 9-month chronic study in cynomolgus 
monkeys support the safety of chronic IVT injections of pegcetacoplan  at monthly or bimonthly 
intervals in humans. 
Pharmacokinetic assessments included in the chronic (9-month) study revealed serum 
concentrations of pegcetacoplan  that were approximately dose-proportional 24 hours after the 
first IVT dose . The serum terminal elimination half -life ( t
1/2) of IVT -administered pegcetacoplan , 
determined in a separate PK assessing a 10  mg/eye dose (in 50 µL),  was 10.4 days although the 
pegcetacoplan  levels measured in the serum following infrequent IVT administration are orders 
of magnitude lower than pharmacological serum levels achieved with SC or IV administration. 
Additional nonclinical  studies in monkeys and rabbits, including assessments of other routes of 
administration (SC and IV), have further defined pegcetacoplan ’s safety profile . Pegcetacoplan  
has been shown to be generally tolerated through all 3 routes of administration assessed (IVT, 
SC, and IV), with no adverse effects observed in safety pharmacology studies (in vivo 
cardiopulmonary telemetry and in vitro hERG inhibition assay) and genotoxicity studies (Ames, 
in vitro  aneugenicity and clastogenicity in TK6 cells, and in vivo clastogenicity in mouse 
micronuclei) .  
Apellis Pharmaceuticals, Inc
Page 23 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Apellis Pharmaceuticals, Inc
Page 24 of 167
Confidential
CCI
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Apellis Pharmaceuticals, Inc
Page 25 of 167
Confidential
CCI
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
4.1.4. Clinical D
ata 
The initial safety and tolerability of pegcetacoplan  following IVT administration in humans was 
tested in an open- label, single dose escalation, Phase I clinical study in patients with wet AMD 
under protocol POT-CP043014 ([STUDY_ID_REMOVED]). The study was conducted in multiple 
ophthalmology clinical sites in the US and Australia. A single dose of pegcetacoplan  was 
administe red on Day 1 to patients suffering from wet AMD currently receiving anti- VEGF 
standard of care. Three escalating doses of pegcetacoplan  administered IVT were studied. 
Three subjects received 4  mg; 3  subjects received 10  mg, and 7 subjects received 20  mg. No 
serious adverse events (SAEs) or drug- related adverse events (AEs) of concern were observed. It 
was concluded that administration of a single dose of pegcetacoplan  IVT up to 20 mg is safe and 
well tolerated.  
A Phase 2 study (Protocol POT-CP121614; NCT 02503332) to assess the safety, tolerability , and 
evidence of activity of multiple IVT injections of pegcetacoplan  in subjects with GA secondary 
to AMD has been completed. The study was conducted at multiple ophthalmology clinical sites 
in the US, Australia , and New Zealand. Subjects were randomized in a 2:1:2:1 manner to either 
receive pegcetacoplan  IVT 15  mg monthly for 12 months; sham IVT monthly for 12 months; 
pegcetacoplan  IVT 15  mg every other month (EOM) for 12 months; or s ham IVT EOM  for 
12 months.  
This study demonstrated a statistically significant slowing of disease progression at Month 12 at 
the pre specified  alpha of 0.1. P egcetacoplan  administered monthly showed a 29% ( P=.008) 
reduction in the rate of GA lesion growth compared to sham, and pegcetacoplan  administered 
EOM  showed a 20% ( P=.067) reduction. P egcetacoplan  has been generally well tolerated. The 
most frequently reported AEs have been related to the injection procedure ( IVT injection), which 
are commonly found in this type of study. An imbalance in new active choroidal 
neovascularization ( CNV ) in subjects treated with pegcetacoplan  was observed and the risk of 
developing new exudation may be increased in subjects with a prior history of neovascular AMD 
in the fellow eye. One subject in the sham arm, 1/81 (1%) was observed to have developed new 
active study eye exudation compared with 25/165 (15%) subjects that received pegcetacoplan  
IVT injections, 26 subjects in total. Of the 25 pegcetacoplan  treated subjects with new active 
CNV, 18  subjects received PM treatment and 7  subjects received pegcetacoplan every other 
month (P EOM ) treatment.  
Seventeen of the 25 (68%) subjects that developed new active study eye CNV had a prior history 
of neovascular AMD in the nonstudy fellow eye. No significant imbalance in history of 
neovascular AMD in the fellow eye was observed among the 3 arms to explain the imbalance in new exudation observed in study eyes. Visual acuity data did not demonstrate clear differenc es 
between subjects developing new study eye exudation compared with those that did not.  
Apellis Pharmaceuticals, Inc
Page 26 of 167
Confidential
CCI
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
A Phase 1b study (Protocol APL2-103; NCT 03777332) to assess the safety of pegcetacoplan  in 
subjects  with GA secondary to AMD and low vision is currently ongoing. Thi s study is being 
conducted at multiple ophthalmology clinical sites  across the US . Subjects receive monthly 
treatment with IVT pegcetacoplan  for 24 months. 
4.1.5. Rationale 
4.1.5.1. Rationale for Pegcetacoplan  for Treatment of Geographic Atrophy  
The rationale for the use of a complement inhibitor in patients with AMD is based on evidence 
from both human and animal studies. Human biochemical, genetic, and clinical lines of evidence indicate that the complement syste m plays a role in the etiology of AMD. Complement 
components including C3, the membrane attack complex , and complement factor H, are present 
in drusen and basal laminar deposits in eyes from patients with AMD.
7,8,9,10  Genetic variants of 
complement factor H,8,11,12,13,14 C3,15,16 complement factor I,17 and other complement 
components18,19,20 have been associated with altered risks for the development of both the 
neovascular and atrophic forms of AMD. Patients with AMD also have signs of systemic complement activation, exhibiting higher serum levels of complemen t factor B, C3a, C5a, 
SC5b-9 ( soluble terminal complement complex ), C3d, and Ba compared to age- matched 
controls.21,22,23,24  
4.1.6. Dose Selection  
A single dose of 15 mg/0.1 mL  injection administered monthly or EOM for 24 months will be 
tested in this study (see Section  7.3.1). Pegcetacoplan  was well  tolerated in a panel of animal 
toxicology studies. A 9 -month, repeat-dose GLP study in cynomolgus monkeys was conducted 
to evaluate the safety of IVT injections of pegcetacoplan  at doses up to 24.8 mg/eye at a 
frequency of 1 injection every 4 weeks.  
In this pivotal chronic toxicological study conducted in monkeys, the NOEL was established as >24.8 mg of pegcetacoplan  delivered IVT every 4  weeks for 9 months using a 100 µL injection. 
The volume of the human vitreous is approximately 4 mL, which is approximately 2.7-fold larger than the mean vitreous volume of cynomolgus monkeys, 1.5 mL.
25 Based on the 
difference in vitreous volume between man and cynomolgus and the NOEL defined in 
nonhuman primates, the human equivalent dose was determined to be 67 mg/eye every 4 weeks . 
The dose (15  mg/injection) of pegcetacoplan  that will be evaluated in this clinical study is 
expected to result in drug concentrations approximately 4.5- fold lower that the NOEL observed 
in cynomolgus monkeys.  
To support appropriate assessments of dose response to pegcetacoplan , pegcetacoplan  is 
administered in 2 different frequencies in the study: monthly and EOM .  
Physician feedback injecting a 200 mg/mL solution in the Phase I (Study POT-CP043014; 
[STUDY_ID_REMOVED]) trial confirmed that 150 mg/mL is the highest pra ctical concentration that can be 
routinely administered, which set the dose of the Phase 2 trial to 15  mg ( ie, 0.1 mL of a 
150 mg/mL solution) . The 15 -mg dose given monthly was found to be the most efficacious in the 
Phase 2 trial. The 15-mg dose given EOM  demonstrated slightly less efficacy but offers a 
reduced treatment burden for patients and physicians.  
Apellis Pharmaceuticals, Inc
Page 27 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
4.2. Risk/Benefit  
The Phase I (Study POT-CP043014; [STUDY_ID_REMOVED]) and Phase 2 (Study POT-CP121614; 
NCT 02503332) studies provide supporting evidence of a positive benefit-risk profile for the use 
of pegcetacoplan  in treating patients with AMD, specifically patients with GA. These 
preliminary results of an up to 28% reduction of GA progression rate support the evaluation of 
pegcetacoplan  in a Phase 3 study.  
The reported safety data from these studies demonstrated an acceptable safety and tolerability profile with no clinically significant safety concerns observed. A total of 178 patients have 
received at least 1 dose (15 mg/injection) of pegcetacoplan  as part of these studies. In the Phase 2 
study in patients with GA an imbalance in new exudation in subjects treated with pegcetacoplan  
was observed. Section  4.1.4 provides a summary of the study design and key results from both 
studies. 
The safety monitoring practices employed by this protocol (complete ophthalmologic exam, IOP 
monitoring, optical coherence tomography ( OCT ), fluorescein angiography (FA) , vital signs, 
hematology, serum chemistry, urinalysis, physical exam, vital signs, and AE questioning) are adequate to protect the subjects’ safety. There are also risks associated with the ophthalmic procedures required for participants in this study. However, these are all standard procedures that are widely performed in ophthalmology. 
In the days following any IVT injection, patients are at risk of developing sterile or infectious 
intraocular inflammation (eg, endophthalmitis). In recent studies conducted with pegcetacoplan  
IVT from a single manufacturer , events of transient moderate and severe intraocular 
inflammation have been observed. Other risks of IVT injection include traumatic cataract, retinal 
detachment, increased IOP, and hemorrhage.  
The amount of blood ( see Section  9.16) planned for collection from each subject over the 
24 months of the study does not pose an undue risk in this patient population. 
There is a potential health benefit for trial participants fr om receipt of study drug. If efficacious, 
pegcetacoplan  is expected to alter the course of GA and slow its rate of progression. 
Apellis Pharmaceuticals, Inc
Page 28 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
5. STUDY  OBJECTIVES 
5.1. Study Objectives  
5.1.1. Primary Objective  
To evaluate the efficacy of pegcetacoplan  compared to sham injection in pat ients with GA 
secondary to AMD assessed by change in the total area of GA lesions from baseline as measured 
by fundus autofluorescence ( FAF). 
5.1.2. Key Secondary Objectives  
To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with GA 
secondary to AMD with respect to: 
• Monocular maximum reading speed (study eye), as assessed by the Minnesota Low-Vision Reading Test ( MNREAD) or Radner Reading Charts (in select countries)  
• Functional Reading Independence Index (FRI) score  
• Normal luminance best  corrected visual acuity (NL -BCVA) score in the study eye  
5.1.3. Secondary Objectives  
• To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with 
GA secondary to AMD with respect to: 
o Low luminance best corrected visual acuity score (LL -BCVA) in the study 
eye  
o Low luminance deficit in the study eye  
o Total area of GA lesion(s) in the study eye  
o Monocular critical print size (study eye), as assessed by MNREAD or Radner Reading Charts (in se lect countries)  
o National Eye Institute Visual Functioning Questionnaire 25- Item Version 
(NEI VFQ -25) distance activity subscale score (in select countries)   
• To evaluate the PK of pegcetacoplan  as assessed by systemic plasma concentration of 
pegcetacoplan  (in select sites)  
5.1.4. Safety Objectives  
• To evaluate the safety  and tolerability of pegcetacoplan  compared to sham  injection in 
patients with GA secondary to AMD as indicated by: 
o Incidence and severity of ocular and systemic treatment -emergent adverse events 
(TEAEs)  
o Incidence of anti -therapeutic antibodies directed against pegcetacoplan  
o Incidence of new active CNV in the st udy eye 
Apellis Pharmaceuticals, Inc
Page 29 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
5.1.5. Exploratory Objectives 
• To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with 
GA secondary to AMD as indicated by: 
o NEI VFQ-25 composite score  
o NEI VFQ-25 near activity subscale score (in select countries)  
o Comparison between study eye and fellow eye in change in GA lesion size  
o To evaluate the binocular maximum reading speed as assessed by MNREAD or 
Radner  Readi ng Charts (in select countries)  
o To evaluate the binocular critical print size as assessed by MNREAD or Radner 
Reading Chart s (in select countries)  
o To evaluate the relationship between genetic polymorphisms associated with 
AMD with GA progression and response to pegcetacoplan  
• To evaluate the incidence of new onset of subclinical CNV in the study eye  
• To assess sensitivity and specificity of a digital r eading speed application to detect 
disease progression/regression (optional, select sites)  
• To assess sensitivity and specificity of a digital visual function application to detect disease progression/regression (optional, select sites).  
Apellis Pharmaceuticals, Inc
Page 30 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
6. PATIENT POPULATION
The study population includes approximately 600 subjects to be randomized at approximately 
100 multinational sites . To participate in the study, subjects must be diagnosed with GA of the 
macula secondary to AMD in the study eye.  
6.1. Patient Selecti on 
6.1.1. Inclusion Criteria 
The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye 
with the worst normal luminance visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be selected as the study 
eye.  
Ocular -specific inclusion criteria apply to the study eye  only, unless otherwise specified. 
1.Age ≥60 y ears.
2.Normal l uminance best corrected visual acuity of 24 letters or better using Early 
Treatment Diabetic Retinopathy Study (ETDRS) charts (approximately 20/320 
Snellen  
equivalent).
3. Clinical diagnosis of GA of the macula secondary to AMD as determined by the  
investigator and confirmed by the reading center.
4.The GA lesion must meet the following criteria as determined by the central reading  
center’s assessment o f FAF
 imaging at screening:
a.Total GA area must be ≥2.5 and ≤17.5 m m2 (1 and 7 disk areas respectively).
b.If GA is multifocal, at least 1 focal lesion must be ≥1.25 m m2 (0.5 disk are as), with 
the overall aggregate area of GA as specified above in 4a.
c.The entire GA lesion must be completely visualized on the macula centered image and 
must be able to be imaged in its entirety and not contiguous with any 
areas of 
peripapillary atrophy.
d.Presence of any pattern of hyperautofluorescence in the junctional zone of GA. 
Absence of h
yperautofluorescence (ie, pattern = none) is exclusionary.1
5. Adequate 
clarity of ocular media, adequate pupillary dilation, and fixation to permit the 
collection of good quality images as determined by the investigator
6.Female subjects must be:
a.Women of non-c hildbearing potential, or
b.Women of childbearing potential (WOCBP) with a negative serum pregnancy test at 
screening and must agree to use protocol-defined methods of contraception for the 
duration of the study and refrain 
from breastfeeding for the duration of the study.
7.Males with female partners of childbearing potential must agree to use protocol-defined  
methods of contraception and agree to refrain from donating sperm for the duration of the 
study.
Apellis Pharmaceuticals, Inc
Page 31 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
8. Willing and able to give informed consent and to comply with the study procedures and 
assessments.  
6.1.2. Exclusion Criteria  
Ocular specific exclusion criteria apply to the study eye  only, unless otherwise specified. 
1. GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy, or toxic maculopathies like plaquenil maculopathy in either eye. 
2. Spherical equivalent of the refractive error demonstrating >6  diopters of myopia or an 
axial length >26 mm. 
3. Any history or active CNV, associated with AMD or any other cause, including any evidence of RPE rips or evidence of neovascularization anywhere based on SD- OCT 
imaging and/or FA  as assessed by the reading center .  
4. Presence of an active ocular disease that in the opinion of the investigator compromises 
or confounds visual function, including but not limited to, uveitis, other macular diseases (eg, clinically significant epiretinal membrane, full thickness macular hole  or 
uncontrolled glaucoma/ocular hypertension). Benign conditions in the opinion of the investigator such as peripheral retina dystrophy are not exclusionary. 
5. Intraocular surgery (including lens replacement surgery) within 3 months prior to randomization.  
6. History of laser therapy in the macula r region.  
7. Aphakia or absence of the posterior capsule. Note: Yttrium aluminum garnet laser 
posterior capsulotomy for posterior capsule opacification done at least 60 days prior to 
screening is not exclusionary. 
8. Any ocular condition other than GA secondary to AMD that may require surgery or 
medical intervention during the study period or, in the opinion of the investigator, could 
compromise visual function during the study period.  
9. Any contraindication to IVT injection including current ocular or periocular infection.  
10. History of prior IVT injection.  
11. Prior participation in another interventional clinical study for IVT therapies in either eye 
(including subjects receiving sham). 
12. Prior pa rticipation in another interventional clinical study for GA in either eye including 
investigational oral medication  and placebo. 
13. Participation in any systemic experimental treatment or any other systemic 
investigational new drug including within 6 week s or 5 half- lives of the active ingredient 
(whichever is longer) prior to the start of study treatment. Note: clinical trials solely 
involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary.  
14. Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the 24-month treatment period unlikely, or would make the subject an unsafe study candidate. 
Apellis Pharmaceuticals, Inc
Page 32 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
15. Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the 
opinion of the i nvestigator is clinically significant and not suitable for study participation.  
16. Known hypersensitivity to fluorescein sodium for injection or hypersensitivity to pegcetacoplan  or any of the excipients in pegcetacoplan  solution.  
6.2. Women of Childbearin g Potential  
WOCBP a re de fined  as premenopausal women physiologi cally capable of beco ming pregnant. 
6.3. Women of Non -Childbearing Potential  
Women of non-childbearing potential are defined as women meeting any of the following criteria:  
• Older than 45 years with amenorrhea for >2  years or older than 60 years with 
amenorrhea for >1  year . Both confirmed by follicle -stimulating hormone and 
luteinizing hormone levels . 
• Has undergone hysterectomy. 
• Has undergone bilateral oophorectomy. 
• Has undergone bilateral salpingectomy. 
6.4. Approved Methods of Contraception  
Approved methods of contraception include:  
• Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation: 
o Oral 
o Intravaginal 
o Transdermal  
• Progestogen-only hormonal contraception associated with inhibition of ovulation: 
o Oral 
o Injectable  
o Implantable 
• Intrauterine device (IUD)  
• Intrau terine hormone- releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomized  partner (provided that partner is the sole sexual partner of the WOCBP 
trial participant and that the vasectomized  partner has received medical assessment 
of the surgical success) 
Apellis Pharmaceuticals, Inc
Page 33 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
• Sexual ab stinence (defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study treatments ). Sexual abstinence is only 
accepted when it is the preferred and usual lifestyle of the subject. 
Subjects must agree to use an approved method of contraception during the study and 90 days 
after their last dose of study drug. 
6.5. Discontinuation of Subjects  
A subject may withdraw from the study at any time for any reason without prejudice to his/her 
future medical care by the physician or at the institution . The investigator or sponsor may 
withdraw the subject at any time (eg, in the interest of subject safety) . The investigator is 
encouraged to discuss withdrawal of a subject from treatment with the investigational product 
(IP) with the medical monitor when possible. 
Subjects who discontinue treatment with the IP can continue participation in the study and 
should be encouraged  to return to the clinical site for as many follow-up visits as they can. In the event that a subject terminate s early  from the study, all early termination procedures should be 
performed even if they are outside the allowed study window.  
The reason for termination, date of stopping treatment  with IP, all follow -up information and the 
total amount of IP  administered  must be recorded in the case report form (CRF) and source 
documents. 
Apellis Pharmaceuticals, Inc
Page 34 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
7. TREATMENT OF SUBJECTS  
7.1. Allocation to Treatment  
Each subject will be assigned a unique screening number after signing the informed consent. 
Subjects who complete the study screening assessments and meet all the eligibility criteria will 
be scheduled to enter the study and randomized on Day 1. As part of the screening process, the 
reading center  will evaluate FAF, OCT , digital color fundus photography, near infrared 
reflectan ce (NIR) , and FA to provide an objective assessment of subject eligibility. Subjects will 
be randomized 2:2:1:1 to receive treatment with pegcetacoplan monthly ( PM), PEOM , sham  
injection monthly (SM), or sham  injection every  other  month (SEOM), respectively.  Table 1 
presents the treatment arms along with the approximate number of subjects and injections per arm. 
The randomization scheme will be generated and maintained by the sponsor, or designee. 
Subject randomization will be stratified by GA lesion area at screening (<7.5 mm
2; ≥7.5 mm2) 
and presence of CNV in the fellow eye (yes; no). Further details on the randomization procedures will be described in the statistical analysis plan .  
7.2. Masking and Minimization of Bias  
The intent of masking is to limit the occurrence of conscious and unconscious bias in the conduct 
and interpretation of the clinical study. Bias could arise from the influence that the knowledge of 
a specific treatment assignment may have on the recruitment and allocation of subjects, their subsequent care, the assessment of endpoints, the handling of withdrawals, and so on. The 
essential aim of masking, therefore, is to prevent identification of the treatments by the subject 
and the masked assessors associated with the conduct of the study until all such opportunities for bias have passed.  
This is a double-masked study. Designated masked study site staff (eg, assistant(s), visual acuity  
technicians, OCT technicians, photographers, technicians administering questionnaires, subjects, reading center  personnel, the assigned evaluating physician(s), and the sponsor ) will be masked 
to treatment assignment. However, the treating physician and any associated support staff involved in performing the IVT or sham injections will be unmasked to study treatment. These 
individuals are not allowed to discuss treatment and/or patient outcome with masked study staff, 
including the evaluating physician. The principal investigator must be masked to subjects’ 
treatment assignment. To prevent bias in treatment assignment, eligible subjects will be 
randomized using a web-based randomization system. Documentation will be put in place to 
avoid unintentional unmasking during the study. All study roles will be clearly documented on 
the site delegation of authority log and once the roles have been designated and executed, these roles should not be switched during the conduct of the study. In unforeseen circumstances, a site 
can contact the sponsor to switch a study staff member from the masked role to the unmasked 
role but not vice versa. 
7.2.1. Unmasking  
In the event of a medical emergency where the knowledge of subject treatment by masked 
individuals (eg, the subject or his/her physician) is required, an individual investigator (or 
designee) will have the ability to unmask the treatment assignment for a specific  subject and 
Apellis Pharmaceuticals, Inc
Page 35 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
share that information with the appropriate parties . All documentation indicating unmasking 
must be retained with the subject’s source documentation in a secure manner. A data monitoring 
committee (DMC ) will be set up to monitor patient safety and review data. The DMC will be 
provided unmasked safety data but will be masked to efficacy data unless this data is deemed medically necessary. Procedures for DMC unmasking will be documented in a DMC charter .  
For regulatory reporting and if required by local regulations, the sponsor will unmask study treatment for all serious, unexpected adverse reactions that are considered to be related to study 
drug. Subjects who have had their treatment assignment unmasked secondary to a serious or 
unexpected AEs or medical emergency will no longer receive study treatment. However, they 
should continue to complete as many of the follow-up visits as possible. 
The study unmasking for the primary analysis at 12 months will be limited to the analysis team 
and personnel only on an as- needed basis . All other personnel in the “masked” role will remain 
masked until the end of study. A document listing out the roles and responsibilities of the individuals participating in the unmasking analysis will be provided prior to the unmasking.  
7.3. Dosage and Administration  
7.3.1. Dose Levels and Treatment Arms  
After randomization and during the treatment phase beginning at Day 1, all subjects will receive a single dose of 15 mg pegcetacoplan /0.1 mL  or sham injection IVT either monthly or EOM  
depending on treatment designation as presented in Table 1 below.  
Table 1: Treatment Arms With Approximate Number of Subjects  
Treatment arms 
Pegcetacoplan  15 mg/0.1 mL monthly for 24 months ( n = approximately 200 subjects; 2 4 pegcetacoplan  
injections)  
Pegcetacoplan  15 mg/0.1 mL every other month for 24 months ( n = approximately 200 subjects; 
12 pegcetacoplan  injections)  
Sham monthly for 24 months (n = approximately 100 subjects; 2 4 sham injections)  
Sham every other month for 24 months ( n = approximately 100 subjects; 1 2 sham injections)  
7.3.2. Treatment Administration  
Only qualified study staff and those delegated the responsibility of study drug administration on 
the delegation of authority log should perform this procedure. All staff should be appropriately 
trained on all procedures prior to performing the procedures. Sites should follow the Visit 
Schedule for order of procedures and assessments.  
Administration of study treatment ( pegcetacoplan  or sham ) can be done on a separate day from 
the assessment visit if both days fall within the visit window. If this occurs on the randomization visit, then the administration of pegcetacoplan  or sham  should be done within 3 days of 
randomization and after approval from the medical monitor . When study treatment 
administration is on a day other than a study visit, then the only assessment that must be done on the day of study treatment administration is the preinjection  IOP.   
Apellis Pharmaceuticals, Inc
Page 36 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
If a subject falls outside the visit window for a dosing visit, the dose should be skipped and the 
subject should be scheduled on time for the next dosing vis it.  
7.3.3. Drug Supplies  
7.3.3.1. Identity of Investigational Product 
Pegcetacoplan  will be supplied as a liquid solution in stoppered glass vials and should be stored 
according to the label. Specific instructions for preparing pegcetacoplan  for the IVT injection 
procedure will be provided in the manual of procedures. Pegcetacoplan  Intravitreal Injection 
15 mg/0.1 mL (150 mg/mL) is a sterile, isotonic solution of pegcetacoplan  in acetate -buffer, 
pH 5.0, containing trehalose. The drug product is packaged in 2R clear Type I glass vials with 
13-mm FluroTec -coated chlorobutyl grey stoppers and sealed with 13- mm 
aluminum/polypropylene flip-off type seals.  
Sham will be provided as empty stoppered glass vials and should be stored according to the 
label.  
7.3.3.2. Storage  
Vials should be automatically stored as per the instructions until ready for use. Each vial should only be used once. Vials should not be shaken and should be protected from sunlight.  
7.3.3.3. Accountability  
Pegcetacoplan  drug product and sham vials will be provided to a designee at the study site and 
must be stored in a pharmacy or otherwise locked and secured, at the temperature specified on 
the label . The drug product supply is accessible only to those individuals authorized by the PI. 
The sponsor will supply sufficient quantities of pegcetacoplan  drug product and sham to allow 
completion of this study. The site should only use the investigational medicinal product provided by the sponsor for use in the study. 
Designated unmasked study staff will provide the study treatments to the subjects in accordance 
with their assigned subject numbers and the randomization schedule. During the study, the receipt of the drugs supplied at the clinical site and of study treatment dispensation for each 
subject will be documented in drug accountability records. These drug accountability records are 
to be kept separate from the patient medical records and other source documents. 
All used vials should be retained by the clinical site until drug accountability monitoring is 
performed and then returned to the sponsor  or designee  or destroyed per sponsor instructions. At 
the conclusion of the study, any unused IP returned to the sponsor  or designee , or destroyed per 
sponsor instructions, and this will be documented in the drug accountability records. 
7.3.4. Intravitreal Pegcetacoplan  Administration  
Subjects receiving active treatment will be administered 0.1 mL  IVT injection of pegcetacoplan  
according to their treatment designation using a thin wall needle. Detailed instructions on drug 
preparation, pre injection  procedures, administration of pegcetacoplan, and postinjection 
procedures will be provided in the manual of procedures . 
Apellis Pharmaceuticals, Inc
Page 37 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Clinic staff involved in the injection tray assembly, anesthetic preparation, and study drug 
preparation and administration will follow appropriate aseptic techniques to mini mize the risk of 
potential AEs associated with IVT injections.  
Administration of pegcetacoplan  is only allowed if pre injection  IOP ≤21 mm  Hg. If necessary , 
antiglaucomatous medication can be given to lower the IOP. To minimize  transient  IOP 
elevation after IVT injection of pegcetacoplan , decompression of the eye must  be performed 
before all pegcetacoplan  injections. This is done by applying moderate pressure to the globe with 
cotton swabs for 30 to 60 seconds during anesthetic preparation.  
In addition to the procedures outlined in the protocol and manual of procedures ( MOP ), 
adherence to specific institutional policies associated with IVT injections will be observed.  
7.4. Sham In jection Administration  
The procedure for sham injection will be the same as that used for IVT injection until the actual 
injection but no actual injection will occur . The injecting physician will only touch the study eye 
with the blunt end of the syringe. No needle or medication will be injected inside the eye. 
Detailed instructions on sham injection procedures and post injection  procedures will be provided 
in the MOP .  
Subjects randomized to the monthly or EOM  sham injection groups will receive SM  or SEOM , 
respectively. The same assessments will be performed as for the subjects in the pegcetacoplan  
groups.  
7.5. Concomitant Therapies  
Any concomitant medications a participant is receiving at the start of the study, within 30 days prior to screening, or that are given for any reason during the study (except for routine 
medications given for ocular procedures required by the protocol, such as topical anesthetic) 
must be recorded in the source documents and CRF including start and stop date and time, dose, route, and indication. In addition, all invasive intraocular procedures from the previous 5 years 
must also be recorded in the source document s and CRF  including start and stop dates. Surgical 
anesthetics, paramedical or alternative therapies ( eg, acupuncture, herbal supplements) should 
also be recorded in the source documents and CRF within 30 days prior to screening. 
Metoclopramide or other agents to prevent nausea induced by fluorescein injection may be 
administered at the discretion of the PI. 
7.5.1. Treatment of New Exudation Related to Active Choroidal Neovascularization in 
the Study Eye  and/or Fellow Eye 
The suspected onset or presence of new  exudation related to active CNV secondary to AMD in 
the study eye and/or fellow eye must be documented in the source documents and CRF. If the 
investigator suspects new  exudation related to active CNV in the study eye based on fundus 
examination and/or OCT findings (eg, subretinal fluid, intraretinal fluid , cystoid macular edema, 
serous pigment epithelial detachment) , a FA and optical coherence tomography angiography 
(OCT -A; select sites only)  must also be captured  following the imaging protocol procedure. All 
images , as outlined above, must be sent to the reading center. The reading center  will provide a 
Apellis Pharmaceuticals, Inc
Page 38 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
report indicating whether or not evidence of active, exudative AMD is present or absent, based 
on the images sent for assessment.  
The determination about initiation of anti-V EGF treatment for the exudation related to active  
CNV is the sole responsibility of the investigator. Treatment with anti-VEGF should start after 
the report is received by the site from the reading center , with the exception of cases with clear 
evidence of disease activity (eg; subretinal hemorr hage, extensive subretinal fluid and/or edema, 
and/or presence of subretinal hyperreflective material) that, in the opinion of the investigator, 
may have a detrimental visual impact if not treated immediately .  
If it is determined that the subject requires anti-VEGF therapy, ranibizumab or aflibercept  should 
be selected and administered by the injecting (unmasked) physician. Ranibizumab should be 
given monthly and aflibercept EOM  after 3 monthly loading doses. The frequency of aflibercept 
can be changed to monthly if deemed necessary by the investigator, however the physician 
should refrain from using as-needed treatment (PRN) or treat and extend protocols. Every effort 
should be made to use the same anti- VEGF the rapy for a subject  during the course of the study 
and all treatments should be documented in the CRF. 
If anti -VEGF therapy is administered in the study eye on the same day as an pegcetacoplan  (or 
sham) injection, the anti-VEGF therapy shall be administered  first and the pegcetacoplan  or 
sham injection shall occur at least  30 minutes after the anti -VEGF injection and only if the IOP 
is ≤21 mm Hg . Antiglaucomatous medication can be given to lower the IOP to the appropriate 
range to allow for the pegcetacoplan  injection .  
In order to avoid potential unmasking, if anti-VEGF and pegcetacoplan  are given at  the same 
visit, the unmasked  physician must perform both procedures. If the anti- VEGF therapy is given 
on a separate day from the pegcetacoplan  administration, either the masked or the unmasked 
physician may perform this injection .  
Treatment with anti- VEGF is allowed in the fellow eye. The treatments for the fellow  eye can be 
administered according to the si te’s standard protocol for CNV treatment. Any treatments or 
therapies administered to the fellow eye within 5 years  of screening and while on study should be 
recorded as a concomitant medication.  
7.5.2. Prohibited Therapies  
The PI should make a determination regarding patient continuation of therapies used to treat 
concomitant medical conditions. Therapies as noted in the inclusion/exclusion criteria are prohibited as specified. 
7.5.3. Endophthalmitis Treatment  
Endophthalmitis cases must be reported as SAEs. The decision to treat a participant for 
endophthalmitis or suspected endophthalmitis will be guided by the clinical judgment of the investigator and in accordance with local guidelines (as applicable). A culture sample should be 
performed prior to making a decision on treatment. The treatment method (pars plana vitrectomy 
vs IVT  injection of antibiotics) and choice of antimicrobial agents are also at the discretion of the 
physician and should follow current standard practice patterns. The decision to use IVT steroids 
(eg, dexamethasone) for the treatment of endophthalmitis is also at the discretion of the 
physician. 
Apellis Pharmaceuticals, Inc
Page 39 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
completion of the 24-month treatment period, subjects will be offered entry into a separate  open-
label study. 
8.1. Study Visit Schedule  
Below is a condensed description of the study visits and the procedures and examinations that 
will be performed. Please refer to the Visit Schedule in Appendix A  to Appendix D  for a detailed 
schedule of procedures/assessments for the monthly and EOM visit schedules. Additional safety assessments not listed in this section or the flow chart may be performed if considered necessary 
at the dis cretion of the investigator. 
8.1.1. Screening Period —Within 28 Days P rior to Randomization/T reatment (Day –28 
to Day –1) 
8.1.1.1. Visit  1—All S ubjects  
Note: All ophthalmic procedures (including imaging) are to be performed on both eyes, except where specified.   
Before any study-specific procedures are performed, the purpose and nature of the study should 
be explained and the patient should read, sign, and date the institutional review 
board/independent ethics committee (IRB/IEC) –approved informed consent form (IC F). The 
individual obtaining consent from the patient and a witness, if applicable, should also sign and 
date the ICF. Once the patient has signed the ICF, a screening number should be assigned to the 
patient. Demographic information, significant medical/s urgical history within the previous 
5 years, invasive ocular procedures within the previous 5 years , and concomitant medications 
used within 30 days prior to screening should be collected (including vitamins and all over-the-
counter as well as prescription  medications).  Complete smoking/tobacco history should also be 
collected.  
Subject eligibility should then be determined by reviewing the inclusion/exclusion criteria and the study eye should be selected. Prior to the administration of fluorescein, blood and urine should be collected for safety labs (including blood for human chorionic gonadotropin/ follicle -
stimulating hormone/luteinizing hormone, if applicable) and vital signs along with a physical examination including weight and height should be performed. 
A complete ophthalmic exam including slitlamp  exam of the cornea, iris, anterior chamber, 
aqueous reaction (cells and flare), dilated fundus exam of the vitreous and retina, and IOP 
measurement. Normal luminance best corrected visual acuity  should be performed prior to 
dilating the eyes. Images should be captured as outlined in the Visit Schedule (FAF, N IR, digital 
color fundus photography, fundus fluorescein angiography [F FA]) and forwarded to the reading 
center  for determination of eligibi lity if applicable .  
8.1.2. Randomization/ Initial Treatment —Day  1—Within 28 Days of S creening  
8.1.2.1. Visit  2—All G roups  
At this visit, all inclusion/exclusion criteria should be reviewed prior to randomization and 
dosing, including the determination of eligibility by the reading center . Subjects will be 
randomized using the interactive web response system . A complete ophtha lmic exam including 
Apellis Pharmaceuticals, Inc
Page 41 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
slitlamp  exam of the cornea, iris, anterior chamber, lens , and aqueous reaction (cells and flare), 
dilated fundus exam of the vitreous and retina, and IOP measurement will be performed and 
imaging collected as per the Visit Schedule.  
All assessments should be performed on the same day. All study visits should be scheduled and 
projected based on the Day 1 visit date with the exception of Visit 2a which should be based on the Day  1 dose date.  
Blood should be drawn for PK and complement  profiling  (select sites only)  and 
anti-pegcetacoplan  antibodies.  
Prior to dilating the eyes, all functional tests should be performed (NL- BCVA, LL -BCVA, and 
MNREAD or Radner Reading Charts [ in select countries ]). Subjects at select sites will be trained 
on how to use the home-based digital applications for visual function and reading speed if the subject decides to participate in this portion. This training must occur after completion of all functional tests (NL -BCVA, LL -BCVA). Tests completed using the digital application  at select 
sites (optional) should be completed prior to dilating the eyes but after completion of all 
functional tests and quality of life measures (NL- BCVA, LL -BCVA, MNREAD or Radner 
Reading Char ts [in select countries] , NEI VFQ-25, and FRI). The subject should be instructed to 
take the electronic device home and to complete the digital application weekly on the same day each week, if possible. The quality of life measures (NEI VFQ -25 and FRI) should be 
administered by the masked site staff.  
Images should be performed including FAF, SD- OCT, OCT -A (select sites), endothelial cell 
count (select sites) , and NIR and sent to the reading center  for evaluation.  
Study drug or sham injection should be performed by the unmasked physician as described in the 
MOP  and the study eye should be monitored post injection as outlined in Section  9.15. A 
follow-up phone call should be scheduled with the subject 4 ± 2 days after randomization Day  1 
to assess for any AEs .  
8.1.3. PK and Complement Sample - Day  7 (Select Sites ) 
8.1.3.1. Visit  2A—All Groups  (Select Sites ) 
Blood should be drawn for PK and c omplement profiling  (select sites) .  
8.1.4. Treatment Phase—24 Months  
8.1.4.1.  Months 1 -12 
8.1.4.1.1. Visits  3-14 (Monthly  and Every -Other- Month  Group s)  
During this phase, there will be clinic visits every month. Dosing and assessments will occur 
monthly in the monthly pegcetacoplan  and sham injection treatment arms. Dosing will occur 
EOM in the EOM pegcetacoplan  and sham injection treatment arms, however, the subjects will 
return monthly for assessments (with no dose given).  
A complete ophthalmic exam including slitlamp  exam of the cornea, iris, anterior chamber, lens , 
and aqueous reaction (cells and flare), dilated fundus exam of the vitreous and retina, and IOP 
measurement will be performed and imaging collected as per the Visit Schedule.  
Apellis Pharmaceuticals, Inc
Page 42 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Blood will be drawn for safety labs, PK, and complement  profile (select sites) , 
Anti-pegcetacoplan  antibodies, and genotyping (Month 2 only) prior to the administration of 
fluorescein as per the Visit Schedule. Samples will be collected for the clinical repository for 
those subjects that consent to this portion.  
Prior to dilating the  eyes, all functional tests will be performed (NL -BCVA, LL -BCVA, and 
MNREAD or Radner Reading Charts [ in select countries ]). Tests completed using the digital 
application  at select sites (optional) will be completed prior to dilating the eyes but after 
completion of all functional tests and quality of life measures (NL -BCVA, LL -BCVA, 
MNREAD or Radner Reading Charts [ in select countries ], NEI VFQ -25, and FRI). At select 
sites t he subject should be instruct ed to take the electronic device home and to complete the 
digital application weekly on the same day each week, if possible. The subject will be instructed 
to bring back the electronic device for the visits specified in the schedule of events. The quality of life measures (NEI VFQ -25 and FRI) will be administered by the masked site staff.  
Imag ing will be performed including FAF, FF A, SD-OCT, OCT -A (select  sites), endothelial cell 
count (select sites) , and NIR and sent to the reading center  for evaluation per the visit schedule.  
Study drug or sham injection should be performed by the unmasked physician as described in the 
MOP  and the study eye should be monitored post injection as outlined in Section  9.15. A 
follow-up phone call should be scheduled with the subject as outlined in the schedule of events.  
In the event that a subject is early terminated from the study, all early termination procedures 
should be performed even if they are outside the allowed study window.  
If the subject would like to discontinue dosing but is amenable to continuing in the study, the site 
should make every effort to have the subject complete as many follow-up visits as possible.  
8.1.4.2. Months 13-24  
8.1.4.2.1. Visits  15-26 (Monthly Group) and 15-20 (Every- Other- Month Group)  
During this phase, clinic visits will follow treatment designation (ie , the monthly subjects will 
return monthly for dosing and assessments and the EOM  subjects  will return EOM  for dosing 
and assessments). At select sites, subject s will complete the home -based digital assessments  
weekly during this period.  
A complete ophthalmic exam including slitlamp  exam of the cornea, iris, anterior chamber, lens , 
and aqueous reaction (cells and flare), dilated fundus exam of the vitreous and retina, and IOP 
measurement will be performed and i maging collected per the Visit Schedule. 
Blood should be drawn for safety labs, PK , and c omplement profile  (select sites),  
anti-pegcetacoplan  antibodies, and genotyping, prior to the administration of fluorescein as per 
the Visit Schedule. Samples will be collected for the clinical repository for those subjects that 
consented to this portion.  
Prior to dilating the eyes, all functional tests should be performed (NL- BCVA, LL -BCVA, and 
MNREAD or Radner Reading Charts [ in select countries ]). The quality of life measures 
(NEI  VFQ -25 and FRI) should be administered by the masked site staff.  
Apellis Pharmaceuticals, Inc
Page 43 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Images should be performed including FAF, F FA, SD-OCT, OCT -A (select sites), endothelial 
cell count  (select sites) , and NIR  and sent to the reading center  for evaluation  per the visit 
schedule.  
IVT (or sham) injection should be performed by the unmasked physician as described in the 
MOP  (noting no injections at Month 24) and the study eye should be monitored post injection as 
outlined in Section  9.15. 
In the event that a subject is early terminated from the study, al l early termination  procedures 
should be performed even if they are outside the allowed study window.  
If the subject would like to discontinue dosing but is amenable to continuing in the study, the site 
should make every effort to have the subject complete as many follow-up visits as possible.  
The completion of the 24-month study period occurs approximately 30 days (monthly treatment 
group) and approximately 60 days (EOM treatment group) after the last visit at which IP is 
administered . The period following last dose  of IP is s ufficient to evaluate the safety of 
pegcetacoplan based on its half- life in the vitreous; further details can be found in the 
pegcetacoplan IB. At the end of the 24-month study period, subjects will have the option to 
enroll into a separate open-label study. 
8.1.5. Early Termination Visit 
A list of all assessments to be performed at the early termination visit can be found on the Visit 
Schedule. All subjects who end the study early for any reason must complete the e arly 
termination visit, however all efforts should be made to have the subject return for as many 
follow-up visits as possible even if dosing does not occur. All ophthalm ic procedu res are to be 
performed on BOTH EYES . 
8.1.6. Unscheduled Visit s 
If a subject returns to the clinical site before their next scheduled visit for an assessment of an 
AEs or at the request of the physician , all safety assessments should be performed and any 
additional assessments as deemed medically necessary by the physi cian.  
 
 
Apellis Pharmaceuticals, Inc
Page 44 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
9. ASSESSMENTS  
The following evaluations will be performed during the study as outlined in the Visit Schedule in 
Appendix A  to Appendix D . Refer to the MOP for detailed descriptions of study- related 
procedures. 
9.1. Informed Consent  
Written informed consent for participation must be obtained before performing any study-
specific assessments. Informed consent for all subjects should be maintained within the subject source documentation.  
9.2. Demographic Information /Medical /Surgical History  
Demographic information will be collected from all subjects including but not limited to date of birth, race/ ethnicity  (where locally permitted) . All significant medical conditions and surgeries 
within the past 5  years should be captured for the subject including chronic and ongoing 
conditions. Any history or current use of tobacco is to be collected. 
9.3. Ocular History /Ocular Procedures  
Ocular history within the previous 5 years should be collected and recorded for all subjects. The 
history should include any significant previous ocular surgeries, procedures and/or medications 
or treatments used for these conditions.  
9.4. Vital Signs  
Vital signs consist of body temperature, respiratory rate, blood pressure (systolic and diastolic), and heart rate measurements .  
On injection visits, vital signs w ill be measured prior to dosing. Vital signs should be taken with 
the patient in a seated position after resting for 5  minutes. Vital signs will be measured before 
venipuncture. 
9.5. Physical Examination  
A physical exam will be performed and should include but should not be limited to an evaluation 
of the eyes, ears, nose, throat, lymph nodes, head, and neurological function. A patient’s height and weight should also be measured at screening. If any abnormalities are noted at screening, the PI, or designee, should determine the clinical significance of the finding and whether this will 
pose any safety risk to the subject. Any changes from baseline should be noted and the clinical significance assessed. Any new, clinically significant, findings should be documented as AEs .  
9.6. Laboratory Analysis of B lood and U rine 
Collection of blood and urine will occur at the study site and the samples will be shipped to a 
central laboratory for analysis. All samples (including urine) should be collected prior to 
treatment and FFA/OCT -A assessments (if applicable). Procedures for the collection and 
processing of blood and urine are provided in the laboratory manual.  
Table 2  presents the laboratory and urine analysis that will be performed.  
 
 
Apellis Pharmaceuticals, Inc
Page 45 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Table 2: Laboratory Sampling and Analysis 
Hematology Chemistry  Urinalysis  Other 
Hemoglobin  
Hematocrit  
Red blood cell count   
White blood cell   count 
with differential  
Platelet count  Blood urea nitrogen Creatinine  
Bilirubin (total, direct 
and indirect)  
Albumin  Alkaline phosphatase   
Aspartate 
aminotransferase  
Alanine aminotransferase  
Creatine kinase  
Glucose  
Electrolytes (sodium, 
potassium, chloride, bicarbonate) pH 
Specific gravity  
Protein  
Glucose Ketones 
Bilirubin  
Blood Nitrite  
Urobilinogen Leukocyte esterase  C3, CH50, AH50  Genotyping  Anti-pegcetacoplan  
antibodies  HCG
a  
FSHb  
LHb  
  
Abbreviations: AH50  = alternative pathway of complement functional test; CH50  = classical pathway of 
complement functional test; FSH = follicle -stimulating hormone; HCG  = human chorionic gonadotropin; 
LH = luteinizing hormone.  
a Serum pregnancy test (ie, HCG) will be per formed for females of childbearing potential at screening only.  
b FSH and LH will be performed for postmenopausal females at screening only.  
The principal investigator, or designee, must review the results of the screening Visit clinical 
laboratory tests (including any retest results) and confirm that these results do not show evidence 
of any medical condition that would make study participation inappropriate. The principal 
investigator, or designee, should also assess any changes from baseline at the follow-up visits and the final visit.  Clinically significant laboratory values are to be recorded as an AEs. 
9.7. Genotyping Samples  
The genetic marker sample will be used to evaluate the relationship between genetic polymorphisms associated with AMD with disease progression and response to pegcetacoplan . 
A whole -blood sample will be collected for genetic marker analysis. These samples will be 
collected only for those subjects who consent to this analysis.  
These samples  will be stored as per the clinical repository  guidelines outlined in Section  9.17 if 
the subject consents to this portion of the study. These samples  will be stored up to 15 years after 
the date of the final closure of the associated clinical database if the patient consented to the 
clinical repository .  
9.8. Urine Pregnancy Test 
Urine pregnancy test will be performed in WOCBP only as outlined in the Visit Schedule in Appendix A  to Appendix D . 
 
 
Apellis Pharmaceuticals, Inc
Page 46 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
9.9. Patient -Reported Outcomes  
Data will be collected via interview -administered questionnaires to assess patient-reported 
outcomes during scheduled visits as outlined in the Visit Schedule. The questionnaire should be 
administered by the masked site staff and should be performed prior to any other assessments being performed that day.  
Questionnaire data will be used to assess subject -reported efficacy of pegcetacoplan  and changes 
in quality of life over time. Questionnaires will be translated into the appropriate language for 
each country or region. 
9.9.1. The National Eye Institute Visual Functioning Questionnaire 25 -Item Version  
The NEI -VFQ is an interviewer -administered questionnaire designed to assess patient- reported 
visual function ( Appendix E ). The NEI -VFQ is to be administered by the masked staff. It is a 
25-item questionnaire with a composite score and covers 12 domains of functional health status 
and well -being (general health, general vision, ocular pain, near activities (select countries) , 
distance activities  (select countries) , social functioning, mental health, role difficulties, 
dependency, driving, color vision, and peripheral vision). Scoring yields 12 subscales  based on 
the 12 domains covered in the questionnaire. These scales are scored from 0 to 100 with higher 
scores indicating better visual function. The recall period is not specified;  however, it is 
important that the patient uses the same recall period each time the questionnaire is administered throughout their participation in the study.  
9.9.2. The Functional Reading Independence  Index   
The FRI will be interviewer -administered and is an individualized assessment of functional 
reading independence ( Appendix F ). The questionnaire has 7 items with 1 total index score. 
Higher levels on the scale represent higher functional reading independence. The recall period i s 
7 days. 
9.10. Best Corrected  Visual Acuity and Low Luminance  Best Corrected  
Visual Acuity  
Best corrected visual acuity (including LL- BCVA) will be measured at each visit as per the visit 
schedule by certified study staff. The study staff performing visual acuity should be masked to 
the treatment  assignment . Best  corrected visual acuity testing will be assessed on ETDRS chart 
starting at a distance of 4  m, performed by a certified visual acuity  examiner, and should precede 
any examination requiring administration of eye drops to dilate the eye or any examination 
requiring contact with the eye.  
The LL-BCVA  acuity will be measured by placing a neutral density trial lens causing a reduction 
of 2.0 log units in luminance. The same requirements apply to measurement of low luminance 
visual acuity as described above for best corrected visual acuity. Low luminance deficit will be 
auto-calculated.  
A Visual Acuity Specifications procedure manual and training materials will be provided to all 
sites. All examiners will require certification prior to performing this assessment  as part of the 
study.  
 
 
Apellis Pharmaceuticals, Inc
Page 47 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
9.11. Minnesota Low -Vision Reading  Test or Radner Reading Ch arts (in 
Select Countries )  
The Minnesota Low-Vision Reading Test or Radner Reading  Charts ( Appendix G ) should be 
administered first monocularly for both eyes and then binocularly. The manual of operations 
should be referenced  for a list of versions that should be administered  based on country. These 
tests should be administered prior to dilating the eyes. 
9.12. Home -Based Functional Digital Applications  (Optional , in Select 
Sites ) 
In addition to in- clinic assessments, visual function and reading speed will also be evaluated 
using applications on an electronic device. Subjects  who decide to participate in this portion will 
be trained on how to use the digital application s at the Day  1 visit and will complete the 
assessments usi ng the digital application in the clinic at Day  1; Months 1-3, Month 6, 12, 18, 
and 24. In-clinic assessments on the digital application should be completed after  completion of 
all functional tests and quality of life measures  prior to dilating the eyes (N L-BCVA, LL -BCVA, 
MNREAD or Radner Reading Charts [ in select countries ], NEI  VFQ -25, and FRI). 
Subjects will also take home the electronic device to complete visual function and reading speed 
assessments weekly beginning at Day  1. Subjects should be instructed to complete the 
assessments on the same day each week and at approximately the same time of day each week , if 
possible.  
9.13. Complete Ophthalmic Exam  
The complete ophthalmic exam will consist of the following: 
• External examination of the eye and adnexa.  
• Routine screening for eyelids/pupil responsiveness (including ptosis, abnormal pupil 
shape, unequal pupils, abnormal reaction to light, and afferent pupillary defect).  
• Slitlamp  examination [cornea, anterior chamber, iris, lens, aqueous reaction (cells and 
flare). Please see Appendix H  for grading scales.  
• Dilated fundus exam including evaluation of retina and vitreous ( ie, posterior segment 
abnormalities, retinal hemorrhage/detachment, and vitreal hemorrhage density and vitreous cells). Vitreal hemorrhage density and vitreous cells grading scales are outlined in Appendix I .  
• IOP measurement —A measurement of IOP will be conducted using either Tono- Pen 
or Goldmann applanation tonometer as outlined in the MOP. This should be performed prior to dilating the eyes and the same method should be used for all measurements in the same subject throughout the study. 
9.14. Ocular Imaging  
The following ocular images will be obtained and sent to the reading center  as outlined in the 
visit schedule . A reading center  manual along with training materials will be provided to all sites  
which will provide information on standardized procedures for the collection, storage, and 
 
 
Apellis Pharmaceuticals, Inc
Page 48 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
transmission of all images.  Prior to any images being taken at the site, site personnel must be 
properly trained and certified and test images and systems and software must be certified and 
validated by the reading center . Only trained and certified site staff delegated the responsibility 
of image collection should perform this task. Ocular images obtained as part of this study are: 
• digital color fundus photographs  
• FA  
• SD-OCT  imaging  
• FAF (Heidelberg Spectralis instrument )  
• NIR  
• Endothelial cell count (specular microscopy) : select sites only  
• OCT -A: select sites only  
If a patient misses a visit during which ocular images should have been taken, the images should be collected at the next scheduled study visit. 
In the event that a subject is suspected to have new active CNV in the study eye and/or the 
fellow eye, an SD -OCT  and F FA using the protocol specified procedures should be performed 
and sent to the reading center to confirm the diagnosis ( Section 7.5.1). In addition, in select sites, 
OCT -A should also be captured according to the study imaging protocol and sent to the reading 
center .  
9.15. Postinjection A ssessment  
The study eye will be assessed after the IVT injection  of pegcetacoplan  or sham  to ensure that 
the injection procedure and/or the study medication have not endangered the health of the eye. 
The initial postinjection  assessments should be done within 5 minutes post injection and include 
a gross assessment of vision (light perception, hand motion).  If the subject passes the gross 
vision test, he/she can be released from the clinic.  If the subject does not pass the gross vision 
test, IOP must be measured  at that time . Additional IOP measurement must be taken 
approximately every 30 minutes  thereafter until IOP ≤30 mm Hg  and the subject is able to be 
released from the clinic.  
All subjects receiving an anti -VEGF  (ranibizumab or aflibercept) and pegcetacoplan/sham  
injection on the same day , should have the IOP measured  prior to and after the anti- VEGF 
(prepegcetacoplan ). The second injection  (pegcetacoplan/sham ) can only be given if the 
IOP ≤21 mm Hg . Anti glaucomatous medication can be given to lower the IOP. The subject can 
only be released from the clinic if the IOP is ≤30 mm Hg . 
Any subject who develops a significant and sustained raise in IOP (>30 mm  Hg) after any 
injection, should be monitored according to the i nvestigator’s clinical judgment and may 
undergo additional procedures and measurements of IOP beyond those specified in the protocol 
as well as IOP lowering procedures. If any concern or immediate toxicity is noted, the subject will remain at the site and will be treated according to the physician’s clinical judgment.  
 
 
Apellis Pharmaceuticals, Inc
Page 49 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
9.16. Blood Volume for Study Assessments  
Table 3: Total Study Blood Volume 
Assay  Number of time 
points  Approximate 
volume per time 
point  * (mL)  Approximate 
sample volume 
over course of 
study (mL)—all 
groups  
Pharmacokineticsa 7 4 28 
Anti-pegcetacoplan antibodies  9 2 18 
*Hematology 8 4 32 
**Chemistry ( incl. HCG/LH)  8 5 40 
FSH/LH  (postmenopausal women 
only) - 5 - 
Genotyping samplea 1 8 8 
Com plement profile (C3, CH50, and 
AH50)a 6 4 24 
Clinical repository ( select sites and 
only subjects that consent to clinical 
repository) 5 14 70 
Total blood volume   220a 
Abbreviations: AH50  = alternative pathway of complement functional test ; CH50  = classical pathway of 
complement functional test; FSH = follicle -stimulating hormone; HCG  = human chorionic gonadotropin; 
LH = luteinizing hormone . 
a  Represents the standard collection volume planned over the duration of the study, actual volume may vary by 
group and across sites . 
* Volume will vary slightly between regions and analyzing labs based on the standard methodology. 
** In some regions, may be included in the chemistry sample based on local methodology . 
9.17. Samples for Clinical Repository ( Optional, Select Sites)  
Apellis intends to apply genomic research across the pegcetacoplan  development program to 
explore how genomic variations may affect the clinical parameters associated with and response 
to pegcetacoplan . Select sites will be asked to collect additional whole-blood samples and 
derivatives thereof in a centrally administere d facility for the long-term storage of human 
biologic specimens. The collection and analysis of these specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for subjects in the future. Specimens for the Genetic 
Biorepository will be collected from subjects who give specific consent to participate in this 
optional research only and this will only be done at a select group of sites.  
Specimens will be  used to achieve the following objectives: 
• To study the association of biomarkers with efficacy, AEs , or disease progression 
• To increase knowledge and understanding of disease biology 
 
 
Apellis Pharmaceuticals, Inc
Page 50 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
• To study drug response, including drug effects and the processes of drug absorption 
and disposition  
• To develop biomarker or diagnostic assays and establish the performance characteristics of these assays  
Future research may suggest other genes, gene categories, proteins, etc. as candidates for influencing not only response to pegcetacoplan  but also susceptibility to AMD for which 
pegcetacoplan  may be evaluated. Thus, this additional genomic research may involve the future 
study of additional unnamed genes or gene categories, but only as they relate to AMD disease susceptibility and drug action.  
9.17.1. Approval by the Institutional Review Board or Ethics Committee 
Collection and submission of biological samples to the c linical repository is contingent upon the 
review and approval of the exploratory research and the c linical repository portion of the I CF by 
each site’s IRB or IEC and, if applicable, an appropriate regulatory body. If a site has not been 
granted approval for c linical repository sampling, this section of the protocol ( Section  9.17) will 
not be applicable at that site.  
9.17.2. Sample Collection  
The following samples will be collected for research purposes, including but not limited to 
research on dynamic (noninherited ) biomarkers related to AMD and related diseases, 
pegcetacoplan , and signaling pathways related to AMD and the complement pathway: 
• Residual whole-blood clinical genotyping sample 
• 14-mL whole- blood sample collected at the specified time  points 
For all samples, dates of consent and specimen collection should be recorded on the associated clinical repository page of the electronic CRF (eCRF ). For sampling procedures, storage 
conditions, and shipment instructions, see the laboratory m anual.  
All collected specimens will be destroyed no later than 15 years after the date of final closure of the clinical database. The clinical repository storage period will be in accordance with the 
IRB/EC- approved I CF and applicable laws (eg, health authority requirem ents).  
9.17.3. Confidentiality and Data Ownership  
Patient medical information associated with clinical repository specimens is confidential and 
may only be disclosed to third parties as permitted by the I CF (or separate authorization for use 
and disclosure of personal health information) signed by the patient, unless required by law. 
Data derived from clinical repository specimen analysis on individual subjects will generally not 
be provided to the subjects or to study investigators unless required by law. The aggr egate results 
of any research conducted using c linical repository specimens will be available in accordance 
with the effective Apellis policy on study data publication. Any inventions and resulting patents, improvements, and/or know-how originating from the use 
of the c linical repository data will become and remain the exclusive and unburdened property of 
Apellis, including the right to sell, license , or assign the invention to another entity.  
 
 
Apellis Pharmaceuticals, Inc
Page 51 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
9.17.4. Consent to Participate in the Clinical Repository  
The I CF will contain a separate section or a separate I CF that will address participation in the 
clinical repository. The investigator or authorized designee will explain to each pat ient the 
objectives, methods, and potential hazards of participation in the c linical repository. Subjects 
will be told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage period. Subjects who decline to participate in the 
clinical repository can still participate in this clinical study. The investigator should document 
whether the patient has given consent to participate by completing the c linical repository 
Research Sample Informed Consent eCRF. In the event of a c linical repository participant’s 
death or loss of competence, the participant’s specimens and data will continue to be used as part 
of the c linical repository research.  
9.17.5. Withdrawal from the Clinical Repository 
Subjects who give consent to provide c linical repository specimens have the right to withdraw 
their specimens from the clinical repository at any time for any reason. If a patient wishes to 
withdraw consent to the testing of his or her specimens, the investigator must inform the sponsor 
in writing of the patient’s wishes using the c linical repository Patient Withdrawal Form and, if 
the study is ongoing, must enter the date of withdrawal on the Clinical Repository Research 
Sample Withdrawal of Informed Consent eCRF. The patient will be provided with instructions 
on how to withdraw consent after the study is closed. A patient’s withdrawal from this Study 
does not, by itself, constitute withdrawal of specimens from the c linical repository. Likewise, a 
patient’s withdrawal from the clinical repository does not constitute withdrawal from this portion 
of the study. 
9.17.6. Monitoring and Oversight 
Clinical Repository specimens will be tracked in a manner consistent with GCP by a quality -
controlled, auditable, and appropriately validated laboratory information management system to 
ensure compliance with data confidentiality as well as adherence to authorized use of specimens 
as specified in this protocol and in the I CF. Apellis monitors and auditors will have direct access 
to appropriate parts of records relating to patient participation in the c linical repository for the 
purposes of verifying the data provided to Apellis. The site will permit monitoring, audits, IRB/EC review, and health authority inspections by providing direct access to source data and documents related to the c linical repository samples. 
 
 
Apellis Pharmaceuticals, Inc
Page 52 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
10. SAFETY EVALUATIONS  
Any clinically significant abnormalities persisting at the end of the study /early withdrawal or end 
of the post treatment  phase will be followed by the investigator until resolution or until a 
clinically stable endpoint is reached. The stu dy includes a number of evaluations to monitor 
safety including monitoring of AEs , post injection  monitoring, laboratory and urine sampling, 
physical examination, and vital signs.  
10.1. Data Monitoring Committee  
An external, independent D MC will be formed with the purpose of reviewing all data across the 
conduct of the study on an ongoing basis. The DMC  will follow a charter that will outline the 
frequency of meetings and the roles and responsibilities of all members. The DMC  will meet at 
the beginning of the study and approximately every 6 months thereafter  and will perform a 
masked review of all relevant events on an ongoing basis. An ad hoc meeting of the DMC  may 
be convened by the sponsor or the DMC  chairperson at any time between the regularly scheduled 
DMC  meetings and data reviews, if warranted by new safety information or for any other reason. 
The DMC  will communicate their recommendations to the sponsor who will notify the 
appropriate health aut horities according to local regulatory requirements.  
 
 
Apellis Pharmaceuticals, Inc
Page 53 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
11. ADVERSE EVENTS  
11.1. Definition  
An AE  is any untoward medical occurrence associated with the use of a drug in humans, whether 
or not it is  considered drug related. An AE can , therefore be any unfavorable and  unintended 
sign, including a clinically significant abnormal laboratory finding, symptom, or disease 
temporally associated with the use of an IP, whether or not considered related to the IP.  
Adverse events can be spontaneously reported by the subject and/or in response to an open 
question from the study personnel or revealed by observation and will be recorded during the 
study at the investigational site. All identified AEs must be recorded and described on the appropriate AE or SAE page of the eCRF. 
Fluctuating or nonsignificant changes in laboratory values do not necessarily qualify for AE 
recording but are still collected and recorded via the appropriate eCRF form, if applicable . If 
these changes in  laboratory values are linked to a diagnosis, this diagnosis should be reported as 
an AE, especially  if the diagnosis constitutes an SAE or leads to discontinuation of 
administration of  IP. 
11.2. Recording Adverse Events  
Adverse events and SAEs will be collected from the signing of the consent form until the last 
visit or early termination  visit, 30 days after the last IP administration  for the monthly treatment 
groups and 60 days after the last IP administration for the EOM treatment groups. 
Any events that occur prior to dosing will be categorized as pretreatment events; events  
occurring after dosing will be recorded as TEAEs (start date of dosing and, therefore, 
categorization of the event will be dependent on randomization assignment). 
For each AE, the investigator will evaluate and report the onset date (and ti me if applicable),  
resolution date (and time if applicable), intensity, causality, action taken, serious outcome, and 
whether or not it caused the subject to discontinue the study. 
If possible, the outcome of any AE that caused permanent discontinuation or was present at  the 
end of the study should be reported, particularly if the AE was considered by the investigator to 
be related to the IP. Subjects experiencing AEs that cause interruption or discontinuation of IP , 
or those experiencing AEs that are present at the last visit or early termination  visit should 
receive follow -up as appropriate.  
All SAEs must be reported to the sponsor/Apellis Safety via eCRF within 24 hours of becoming aware of the event, whether or not the event is deemed treatment -related. If the electronic data 
capture (EDC) system is not operational (or for paper- based study[ies]), the site must complete  
the paper SAE form and email to  immediately and  also within 24 hours of 
bec 
oming aware of the event. The reported information submitted as a paper SAE must be 
entered into the EDC
 system once it becomes operational.  
Adverse events will be coded in accordance with the Medical Dictionary for Regulatory Activities (Me
dDRA). If known, the diagnosis of the underlying illness or disorder should be 
recorded, rather than its individual symptoms. 
 
 
Apellis Pharmaceuticals, Inc
Page 54 of 167
Confidential
CCI
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
11.3. Reporting Adverse Events  
The sponsor has the responsibility to inform concerned health authorities, ethic committees, and 
investigators about suspected unexpected serious adverse reactions ( SUSARs ) in line with GCP 
guidance and applicable regulatory requirements. 
If required, specific SAEs should be reported to the concerned ethic committees in compliance 
with local requ irements.  
11.3.1. Relationship of Events to Study Treatment  
All AEs that occur during this study will be recorded. The investigator will review each event  
and assess its relationship to study treatment  (defin itely related, possibly related, unlikely related, 
not related, unknown). The date and time of onset, time relationship to drug dosing, duration, and outcome (recovered/resolved, recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, fatal, or unknown) of each event will be noted.  
The following definitions should be considered when evaluating the relationship of AEs and 
SAEs to the study treatment: 
Defin itely 
Related  • Event or laboratory test abnormality, with plausible time relationship to drug intake 
• Cannot be explained by disease or other drugs 
• Response to withdrawal plausible (pharmacologically, pathologically)  
• Event definitive pharmacologically or phenomenologically ( ie, an objective and 
specific medical disorder or a recognized pharmacological phenomenon)  
• Rechallenge sat isfactory, if necessary  
Possibly 
Related  • Event or laboratory test abnormality, with reasonable time relationship to drug intake 
• Could also be explained by disease or other drugs 
• Information on drug withdrawal may be lacking or unclear 
Unlikely  
Related  • Event or laboratory test abnormality, with a time to drug intake that makes a 
relationship improbable (but not impossible) 
• Disease or other drugs provide plausible explanations  
Not Related  • Event or laboratory test abnormality, is plausibly related to the participant’s clinical 
state, underlying disease, or the study procedure/conditions 
• Time relationship to drug intake makes a relationship unreasonable 
• Other obvious causes for event or laboratory test abnormality exist 
Unknown • Report suggests an adverse event, however, cannot be judged at this time because information is insufficient or contradictory  
• More data for proper assessment is needed, or additional data is under examination 
 
 
Apellis Pharmaceuticals, Inc
Page 55 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
11.3.2. Severity of Events  
The following definitions should be considered when evaluating the severity of AEs and SAEs: 
Mild  Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention 
not indicated. 
Moderate Minimal, local or non invasive intervention indicated; limiting age -appropriate 
instrumental ADL  a. 
Severe  Medically significant but not immediately life -threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self- care ADLb. 
Note : An experience may be severe but may not be serious, eg, severe headache).  
A semi colon indicates ‘or’ within the description of the grade.  
Note: Activities of Daily Living (ADL)  
a Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc.  
b Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden.  
11.4. Seriou s Adverse Events  
An SAE  is any AE or suspected adverse reaction that , in the view of either the investigator or 
sponsor, results in any of the following outcomes: death; life -threatening; inpatient 
hospitalization or prolongation of existing hospitalization; a persistent or significant incapacity 
or substantial disruption of the ability to conduct normal life functions; or a congenital 
anomaly/birth defect.  
Important medical events that may not result in death, be life- threatening *, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in the above definition.  
Examples of such medical events include allergic bronchospasm requiring intensive treatment in 
an emergency room or at home; blood dyscrasias or convulsions that do not result in inpatient hospitalization ; or the development of drug dependency or drug abuse. 
*Life -threatening is defined as an AE or suspected adverse reaction, which , in the view of either 
the Investigator or Sponsor places the subject at immediate risk of death as it occurred . It does 
not include an AE or s uspected adverse reaction that, had it occurred in a more severe form, 
might have caused death.  
Unexpected Adverse Event 
An AE is considered “unexpected” if it is not listed in the Reference Safety Information section 
of the IB. 
11.5. Treatment and Follow-up of Adverse Events  
AEs (whether serious or nonserious), including clinically significant abnormal laboratory test values, will be evaluated by the investigator and treated and/or followed up until the symptoms 
or value(s) return to baseline or are clinically stable. Treatment of AEs will be performed by 
appropriately trained medical personnel, either at the clinical site or at a nearby hospital 
 
 
Apellis Pharmaceuticals, Inc
Page 56 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
emergency room. When appropriate, medical tests and/or examinations will be performed to 
document resolution of the event(s).  
AEs continuing after completion of the study will be followed up by telephone or with visits per the discretion of the investigator. If possible, the outcome of any AE that caused discontinuation 
from the study or was present at the end of the study should be reported, particularly if the AE 
was considered by the investigator to be related to the study drug. 
11.6. Pregnancy  
Although pregnancy is not an AE, all pregnancies and suspected pregnancies (including a 
positive pregnancy test regardless of age or disease state) occurring with a female subject or the 
female partner of a male subject, must be followed to conclusion to determine their outcome and are considered immediately reportable events.  
The pregnancy, suspected pregnancy, or positive pregnancy test must be reported to Apellis Safety within 24 hours of the investigator’s awareness using the paper Pregnancy Report Form. The Pregnancy  Report Form shall be signed and dated by the investigator and submitted via 
email to . 
The investigator must follow the subject until completion of the pregnancy and must report the outcome of the pregnancy (
eg, delivery, termination, etc.) and neonatal status up to 12 months 
postdelivery. An abnormal outcome is defined as any pregnancy that results in the birth of a child with persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions (formerly referred to as disabilities), congenital anomalies, or birth defects. In the event of an abnormal outcome, an SAE Report Form will be required.   
11.7. Disease Progression  
Normal progression or worsening of the medical condition under study ( eg, vision loss due to the 
progression of GA in either eye ), by itself, does not necessarily constitute an AEs  unless the 
change can be reasonably attributed to an action of the test article and not only to its lack of 
efficacy.  Disease progression that requires an intervention ( eg, administration of IVT anti- VEGF 
agents for neovascular AMD ) should be recorded as an AEs  in the eCRF .  
11.8. Withdrawal  
Participants may choose to discontinue from treatment or to completely withdraw from this study for any reason at any time without penalty or prohibition from enrolling in other clinical 
protocols. 
Participants wishing to withdraw from the study completely will be offered an early termination 
visit. This early termination visit will include the examinations outlined in  Section  8.1.5. 
Participants wishing to discontinue treatment but willing to continue with other study procedures, will return to the clinical site for follow -up visits, as per protocol, until Month 24. 
Additional information on subject discontinuation is provided in Section 6.5. 
 
 
 
Apellis Pharmaceuticals, Inc
Page 57 of 167
Confidential
CCI
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
12. DATA MANAGEMENT AND STATISTICAL CONSIDERATIONS  
12.1. Data Collection  
The investigators’ authorized site personnel must enter the information required by the protocol 
on the CRF. A study monitor will visit each site in accordance with the monitoring plan and 
review the CRF data against the source data for completeness and accuracy. Discrepancies 
between source data and data entered on the CRF will be addressed by qualified site personnel. When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting.  
12.2. Clinical Data Management  
Data are to be entered into a clinical database as specified in the contract research organization ’s 
data management plan. Quality control and data validation procedures are applied to ensure the validity and accuracy of the clinical database.  
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerize d and manual procedures. Data qu eries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.  
12.3. Statistical Analysis Process  
The study will be analyzed by the sponsor or its agent.  
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for summarizing other study information such as subject disposition, demographics and baseline 
characteristics, IP exposure, and prior and concomitant medications. The SAP will also include a 
description of how missing, unused, and spurious data will be addressed.  
To preserve the integrity of the statistical analysis and study conclusions, the SAP will be 
finalized prior to database lock. All statistical analyses will be performed using SAS  (SAS 
Institute, Cary, NC 27513). 
12.4. Planned Interim Analysis and Data Safety Monitoring Committ ee  
No interim analysis is planned for this study. During the study, patient safety will be monitored 
on a continuous basis by the m edical monitor until the last patient completes his or her last 
scheduled study assessment. 
An independent DMC  will also be established to provide an ongoing, independent review and 
assessment of the safety data, and to safeguard the interests and  safety of the participating 
patients in the s tudy. The ongoing review of SAEs and other responsibilities of the DMC  will be 
described  in the DMC  charter . 
The overall Type I (alpha) error rate for the study will be 0.05. To accommodate DMC  data 
reviews, the alpha available for efficacy hypothesis testing will be reduced by 0.0001 for each 
 
 
Apellis Pharmaceuticals, Inc
Page 58 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
DMC  review . The study is expected to have 3 -4 DMC  data reviews prior to the primary analysis 
of 12-month data and one review afterward.  
12.5. Sample Size Calculation and Power Considerations  
Subjects will be randomized in a 2:2:1:1 ratio to receive treatment with PM, PEOM , SM , or 
SEOM . The annual growth rate in GA lesion area is expected to have a mean of 1.47, 1.70, and 
2.13 mm2/year for PM, PEOM , and sham -pooled groups, respectively, as estimated from the 
results of a Phase 2 trial for pegcetacoplan . The standard deviation of the lesion growth is 
estimated to be 1.50 mm2 based on the same Phase 2 trial data or 1.25 mm2 based on natural 
history data.26 The following table provides an approximation of the study power for a sample 
size of 200 subjects in each group (ie, a total enrollment of 600 subjects) under different alpha 
values and standard deviations. The approximation is calculated using PROC POWER one- way 
analysis of variance, SAS 9.4. The study power is likely larger when utilizing the longitudinal data to model the primary endpoint. The actual study power may also vary based on the distribution of the stratification factors (ie, lesion area at s creening, presence of CNV in fellow 
eye), and site enrollment.   
Table 4: Power to Detect a Difference Among  3 Groups With  an Equal Size of 200 Subjects  
Common standard 
deviation  (mm2) Alpha  
(2-sided)  Power for a true mean of 1.47,  1.70, and 2.13 mm2/year for PM , 
PEOM, and sham , respectively  
PM vs sham  PEOM vs sham  Overall  
(among 3 groups)  
1.25 0.0495 >99.9% 92.9% 99.9% 
1.25 0.0248 99.9% 88.2% 99.7% 
1.40 0.0495 99.7% 86.5% 99.3% 
1.40 0.0248 99.3% 79.4% 98.6% 
1.50 0.0495 99.2% 81.5% 98.4% 
1.50 0.0248 98.4% 73.1% 97.0% 
Abbreviations: PM = pegcetacoplan monthly, PEOM  = pegcetacoplan every  other  month . 
12.6. Statistical Analysis Set s  
The safety set  will consist of all subjects who receive any amount of IP. 
The intent -to-treat (ITT) set  will include all randomized subjects. Subjects will be analyzed in 
the treatment arm assigned at randomization with the 2 sham treatment arms being combined 
into a single ‘control’ group.  
The modified ITT set  will include all randomized subjects who recei ve at least 1 injection of 
pegcetacoplan  or sham  and have baseline and at least 1 post baseline value of GA lesion in the 
study eye as assessed by FAF. The per-protocol (PP) set  will include all ITT subjects who follow the protocol without any 
major deviation(s) that could impact the integrity of the data. A detailed description of the 
reasons for exclusion from the PP population will be included in the SAP. 
 
 
Apellis Pharmaceuticals, Inc
Page 59 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
12.7. Efficacy Analyses  
The primary, secondary, and exploratory efficacy analyses will be performed using t he ITT set 
and presented by treatment group. 
12.7.1. Primary Efficacy Analysis 
The primary efficacy endpoint is the change from baseline to Month 12 in the total area of GA 
lesion(s) in eyes injected with pegcetacoplan , either PM or PEOM , or sham injections. GA lesion 
area (mm2) as measured by a quantified central reading center  based on FAF images. The 
primary analysis will be the comparison of pegcetacoplan , either PM or PEOM  versus the 
combined 2 sham arms ( the 2 sham arms will be combined into a single ‘control’ group). 
The null and alternative hypotheses for the primary efficacy analysis are:  
H0: µS = µ PM   vs  H A:  µ S ≠ µ PM, and  
H0: µS = µ PEOM vs  H A:  µ S ≠ µ PEOM  
Note: Here µ indicates each group’s respective mean change from baseline to Month 12 in GA 
lesion area for the comparison of the primary endpoint. 
A mixed effect model for longitudinal data will be used to analyze the change from baseline in 
GA lesion area. The mode l will include treatment, and presence of CNV in the fellow eye as 
fixed effects; baseline GA lesion area (at screening), time (in months) as a factor ; as well as the 
time × treatment interaction term. All available data up to 12 months will be included in the 
model for the primary analysis. The mean change from baseline to 12 months will be estimated 
from the model (ie , LS mean) and compared between each of the pegcetacoplan  arms to the 
sham control. For other time point of interest, LS mean change from ba seline will be estimated 
and compared between treatments.  Unstructured variance covariance will be used . 
For the analysis of final study data, a similar model including data up to 24 months will be used and LS means at time  points of interest will be estimated and compared between treatment.  
As indicated in an earlier section, the study is expected to have an approximately 5 DMC  data 
reviews . Allocating an alpha level of 0.0001 for each DMC  data review, the alpha level remains 
for the efficacy analysis at 0 .0495 to maintain an overall study alpha of 0.05. 
The hypothesis testing strategy for the primary and secondary  efficacy endpoint s will be based 
on the Gate-keeping multiple testing procedures controlling for the study wide type I error strongly at 2- sided  0.0495 as follows :  
Step 1. The  mean GA lesion growth at 12 months will be compared between the PM group 
and the Control at the α level of 0.0495. If the null hypotheses of no difference between groups in this step is rejected, the testing proceeds to Step 2  and Step 3 . If it’s not rejected, 
the testing procedure stops at this step.  
Step 2. The  mean GA lesion growth at 12 months will be compared bet ween the PEOM  
group and the Control at the α1  level . If the null hypotheses of no difference between groups 
in this step is rejected, the α1 level will be passed down to Step 3 . The actual value of α1 will 
be specified in the SAP and it will be defined to ensure an adequate power of at least 80% for 
the comparison in this step. 
 
 
Apellis Pharmaceuticals, Inc
Page 60 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Step 3. The  mean GA lesion growth at 24 months will be compared between the PM group 
and the Control at the α level of 0.0495 if the null hypotheses are rejected at both Step 1  and 
Step 2 ; or at the α level of (0.0495 – α1)  if Step 2  testing does not reject the null hypothesis. 
If the null hypothesis at this step is rejected, the α level used at this step will be passed down 
to the next step of testing. If it’s not rejected, the testi ng procedure stops at this step.  
Step 4. The prioritization and alpha allocation for the remaining secondary endpoints will be specified in the SAP.  
The following sensitivity and supportive analyses will be performed to evaluate the robustness of the resu lts from the primary analysis method: 
• Analyses will be repeated using the modified ITT and PP sets  
• Primary and secondary endpoints will also be summarized with no pooling of the 2 sham arms . The comparison for pegcetacoplan  and sham injection within each dose 
regimen (i e, PM vs SM and PEOM  vs SEOM) will be conducted 
• Multiple imputation methods and other sensitivity analyses will be explored, and 
details will be provided in the SAP 
12.7.2. Secondary Efficacy Analysis 
The key secondary and secondary endpoints will be analyzed in the same fashion as the primary endpoint using mixed effect model. The binary secondary endpoints will be analyzed using 
Cochran -Mantel -Haenszel test stratified by the randomization stratification factors. Hypothesis 
testing for 3 key secondary endpoints will be performed in the order specified. The SAP will 
provide more details on multiplicity adjustment and the approach for alpha spending among the endpoints.  
Key Secondary Efficacy Endpoints  
• Change from baseline in monocular maximum reading speed (study eye), as assessed 
by MNREAD or Radner Reading Charts at Month 24 (in select co untries ). 
• Change from baseline in F RI score, at Month 24. 
• Change from baseline in NL-BCVA at Month 24 as assessed by ETDRS chart.  
Secondary Efficacy Endpoints 
• Change from baseline in LL-BCVA at Month 12 and Month 24 as assessed by 
ETDRS chart.  
• Change from baseline in low luminance deficit at Month 12 and Month 24. 
• Change from baseline at each planned assessment in the total area of GA lesion(s) in the study eye (in mm
2) as assessed by FAF.  
• Change from baseline in monocular critical print size (study eye), as assessed by MNREAD or Radner Reading Charts, at Month 12 and Month 24 (in select countries).  
• Change from baseline in the NEI VFQ-25 distance activity subscale score at Month 
12 and Month 24 (in select countries) .  
 
 
Apellis Pharmaceuticals, Inc
Page 61 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
• Systemic Plasma concentration of pegcetacoplan  over time  (select sites).  
12.7.3. Exploratory Efficacy Analysis 
Summary statistics will be provided for the following exploratory endpoints: 
• Change from baseline in NEI VFQ-25 composite score at Month 12 and Month 24.  
• Change from baseline in NEI VFQ-25 near activity subscale score at Month 12 and 
Month 24 (in select countries) . 
• Comparison between study eye and fellow eye in change in GA lesion size from baseline to Month 12 and Month 24.  
• Binocular maximum reading speed as assessed by MNREAD or Radner Reading 
Charts over time (in select countries) .  
• Binocular critical print size as assessed by MNREAD or Radner Reading Charts over 
time (in select countries) . 
• Relationship between genetic polymorphisms associated with AMD with GA progression and response to pegcetacoplan . 
• Incidence of new onset of subclinical CNV in the study eye.  
• Assess sensitivity and specificity of a digital reading speed application to detect 
disease progression/ regres sion (optional, select sites).  
• Assess sensitivity and specificity of a digital visual function application to detect 
disease progression/regression (optional, select sites).  
12.8. Safety Analyses  
Adverse events will be collected from the time of the first study drug administration until a 
subject completes the study or discontinues prematurely. Treatment- emergent adverse events are 
defined as those AEs that develop or worsen after the first dose of study medication and up to 30 days beyond the last dose of study medication. The current version of MedDRA will be used 
to classify all AEs. Treatment- emergent AEs will be summarized by System Organ Class and 
Preferred Term, in accordance with the MedDRA coding dictionary. The number of subjects 
reporting each AE P referred Term will be tabulated for all TEAEs and separately for those 
considered as related to study treatment by the investigator or designee. Number of subjects reporting SAEs will also be tabulated. Adverse event summaries will be presented for each treatment group separately.  
Adverse events will be summarized by MedDRA coding terms, and separate tabulations also will be produced for related AEs (those considered by the investigator as definitively drug related), 
SAEs , and discontinuations due to AEs . Vital signs data and findings from physical and 
ophthalmologic examinations will be tabulated for changes over time on study. Laboratory parameters will be summarized for changes across study by using descriptive statistics. Separate summaries will be pr epared for systemic (nonocular ) and ocular AEs, with events in the study 
eye and nonstudy eye summarized separately  
 
 
Apellis Pharmaceuticals, Inc
Page 62 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
12.8.1. Anti -Therapeutic Antibodies  
Data on anti -therapeutic antibodies directed against pegcetacoplan  will be summarized by the 
number and percentage of subjects with confirmed positive anti-therapeutic antibodies .  
12.8.2. Death  
Patient deaths and primary cause of death will be summarized.  
12.8.3. Ocular Assessments  
Descriptive summaries will be generated for ocular assessments such as visual acuity  and IOP.  
12.9. Pharmacokinetic Analyses  
Pharmacokinetic parameters will be determined from the plasma concentration -time data for  
Pegcetacoplan by noncompartmental  analysis. The PK endpoints will include but not be limited 
to the following PK  parameters:  
• AUC0 -tau:  Area under the curve for the defined interval between doses 
• Cmax: Maximum concentration occurring at T max 
• Tmax: Time of maximum observed concentration sampled during a dosing interval 
Summary statistics (number of observations, mean, standard deviation, coefficient of variation, 
median, maximum, minimum, and geometric mean) will be determined for all PK  parameters by 
overall and by assessment time. Plasma concentrations at each nominal sampling time will also 
be sum marized using descriptive statistics.  
12.10.  Handling of Missing Data  
All efforts will be made to minimize missing data. A full description of the imputation methods 
will be provided in the SAP.  
12.11.  Visit Windows  
Analysis visits will be derived with windows for the monthly visits to assess the primary endpoint. Baseline is defined as the date of randomization. If 2 or more treatment visits occur within a window, the closest visit to the target day will be used as that analysis visit; if 2 visits are equidistant from the scheduled analysis visit day, the later analysis visit will be used.  
 
 
Apellis Pharmaceuticals, Inc
Page 63 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
13. ETHICS 
13.1. Ethical Conduct of the Study  
This research will be carried out in accordance with the protocol, applicable regulations, the 
ethical principles set forth in the Declaration of H elsinki, and the International Council for 
Harmonisation ( ICH) Harmonized Tripartite Guidance for GCP , E6, R1. 
13.2. Institutional Review Board/Ethic Committee  
The study protocol, any amendments to the protocol, ICF , the IB, and other study- specific 
information will be reviewed and approved by the IRB/IEC. The study will not be initiated until 
the IRB/IEC has approved the protocol or a modification thereof. All records pertaining to 
IRB/IEC submission and approval should be kept in the site’s regulatory files and sponsor’s trial master file ). 
The IRB/IEC must be constituted and operate in accordance with the principles and requirements described in ICH Guidance E6 and national and local regulations as deemed appropriate. 
13.3. Subject Information and Consent  
The principal investigator, or designee, is responsible for obtaining an informed consent. A 
written informed consent, in compliance with ICH Guidance E6, must be obtained from each subject  at the screening visit,  prior to performing any study- related procedures.  
The purpose of the study, the procedures to be carried out, and the potential hazards will be described to the subjects in nontechnical  terms. The subject will be given sufficient time to 
consider the study’s implications before deciding to participate in the study. The subject and/or legal guardian will be required to sign and date an ICF and will be assured that they may withdraw from the study at any time without jeopardizing their medical care. The PI shall retain 
the original, signed informed consent for study participation in the subject’s medical record and 
shall provide the subject and/or legal guardian with a copy of the signed consent. 
If there are any changes/amendments to the approved protocol, which may directly affect the 
subject’s decision to continue participation in the study, the ICF shall be amended to incorporate 
the changes to the protocol and the subject must re- sign the IRB/IEC approved amended ICF.  
 
 
Apellis Pharmaceuticals, Inc
Page 64 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
14. ADMINISTRATIVE CONSIDERATIONS  
14.1. Direct Access to Source Data/Documents  
The principal investigator , or designee, must maintain, at all times, the primary records ( ie, 
source documents) of each subject’s data for data verification. Examples of source documents 
are medical records, laboratory reports, study drug records, and printed CRF pages t hat are used 
as the source.  
The investigator will permit trial-related monitoring, audits, and inspections by the sponsor 
and/or its designee, IRB/IEC, and the regulatory agencies at any time during the study. The 
investigator will ensure that the auditor is allowed direct access to the source data, medical records, eCRFs, and the site’s regulatory file for the study and any other pertinent information.  
14.2. Quality Control and Quality Assurance  
This study is to be performed in full compliance with the protocol, GCP, and applicable regulatory requirements. The principal investigator, Sponsor, and/or its designee are responsible 
for ensuring that the study staff receive appropriate training on the protocol, study procedures, and any other relevant informa tion.  
Quality assurance and quality control systems are implemented and maintained using written Investigative site, sponsor and/or designee standard operating procedures to ensure that the study 
is conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirement(s) and local laws, rules, regulations. 
Quality control checks will be applied at each stage of data handling ( eg, edit checks) to ensure 
that all data are reliabl e and have been processed correctly. 
14.3. Monitoring  
On-site monitoring will be performed by the sponsor’s designee for the duration of the study. 
The monitor will ensure that the study is conducted, recorded, and reported in accordance with 
the protocol, standard operating procedures, GCP, and the applicable regulatory requirements. 
The monitor will verify the accuracy and completeness of the eCRF entries, source documents, 
and other study- related records against each other . The investigator, or designee, will provide 
direct access to source data/documents for study- related monitoring . It is important that the 
investigator and the investigator s ite staff are available at these visits. The monitor will record 
the date of each visit together with a summary of the status and progress of the study. Proposed 
actions will be documented in writing to the investigator. 
14.4. Data Handling and Record Keeping  
The investigator must maintain all documentation related to this stud y. All essential documents 
(as defined in the ICH Guideline E6 and applicable local regulations) and the data generated in connection with this study, together with the original copy of the final report, will be retained for 
at least 2  years after the last approval of a marketing application in an ICH region and until there 
are no pending or contemplated marketing applications in an ICH region or at least 2 years have 
elapsed since the formal discontinuation of clinical development of the IP. These documents 
 
 
Apellis Pharmaceuticals, Inc
Page 65 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
should be retained for a longer period if required by the applicable regulatory requirements or by 
an agreement with the sponsor. 
It is the responsibility of the sponsor to inform the investigator/Institution as to when these 
documents no longer need to be retained.  
14.5. Protocol Amendments 
Any amendments to the study protocol deemed necessary as the study progresses will be discussed between sponsor and the investigator. The investigator will not implement any changes 
to the protocol without an agreement by the s ponsor and prior review and documented 
approval/favorable opinion from the IRB/IEC of an amendment, except where necessary to eliminate immediate hazards to study subject or when the changes involve only logistical or administrative aspects of the study (eg, change in staff, telephone numbers).  
Changes resulting in amendments will be made jointly between the sponsor and the investigator and must be confirmed in writing. Amendment(s) will be approved and signed off in the same way as the protocol.  
14.6. Report Format  
According to the ICH Harmonized Tripartite Guideline (Organization of the Common Technical 
Document for the Registration of Pharmaceuticals for Human Use M4 and the ICH M2 Expert 
Working Group), the final report will be written according to the ICH E3 Guideline (Structure and Content of Clinical Study Reports). 
14.7. Finance and Insurance  
Finance and insurance will be addressed in a clinical trial agreement between the sponsor and the 
investigator/institution . 
14.8. Publication Policy  
The data generated fo r this study are considered confidential information and are the property of 
the sponsor. All study information provided to the PI and site personnel by the sponsor shall not 
be published or disclosed to a third party without the prior written consent of the sponsor.  
Apellis will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Apellis adheres to external guidelines 
(eg, Good Publication Practices 2) when forming a publication steering committee, which is 
done for large, multicent er Phase 2-4 and certain other studies as determined by Apellis. The 
purpose of the publication steering committee is to act as a non commercial  body that advises or 
decides on dissemination of scientific study data in accordance with the scope of this poli cy. 
All publications relating to Apellis products or projects must undergo appropriate technical and 
intellectual property review, with Apellis agreement to publish prior to release of information. 
The review is aimed at protecting the sponsor’s proprietary information existing either at the commencement of the study or generated during the study. To the extent permitted by the 
publisher and copyright law, the investigator will own (or share with other authors) the copyright 
 
 
Apellis Pharmaceuticals, Inc
Page 66 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
on his/her publications. To the extent that the investigator has such sole, joint, or shared rights, 
the investigator grants the sponsor a perpetual, irrevocable, royalty- free license to make and 
distribute copies of such publications. 
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral, or other form.  
Subject to the terms of the paragraph below, the investigator shall have the right to publish the study results, and any background information provided by the sponsor that is necessary to 
include in any publication of study results, or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Apellis, the institution and investigator 
shall with hold submission of such publication for up to an additional 60 days to allow for filing 
of a patent application. 
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the sponsor within an 18-month period after conclusion, abandonment, or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may individually publish the study results from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single- site data being presented.  
Unless otherwise required by the journal in which the publication appears, or the forum in which it is made, authorship will comply with the International Committee of Medical Journal Editors current standards. Participation as an investigator does not confer any rights to authorship of 
publications. 
14.9. ClinicalTrials.gov  
This study will be listed with ClinicalTrials.gov.  
14.10.   Termination of Study  
The sponsor reserves the right to suspend or discontinue this study for administrative and/or 
safety reasons at any time. The investigator reserves the right to discontinue dosing subjects at 
any time for safety reasons.   
 
 
Apellis Pharmaceuticals, Inc
Page 67 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
15. REFERENCES 
1. Holz FG, Bindewald -Wittich A, Fleckenstein M, et al. Progression of geographic atrophy and 
impact of fundus autofluorescence patterns in age- related macular degeneration. American 
journal of ophthalmology. 2007;143(3):463-472. 
2. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through 
the year 2050: the potential impact of new treatments. Archives of ophthalmology. 
2009;127(4):533-540. 
3. Friedman DS, O'Colmain  BJ, Munoz B, et al. Prevalence of age-related macular degeneration in 
the United States. Archives of ophthalmology. 2004;122(4):564-572. 
4. Holz FG, Strauss EC, Schmitz -Valckenberg S, van Lookeren Campagne M. Geographic atrophy: 
clinical features and potenti al therapeutic approaches. Ophthalmology. 2014;121(5):1079-1091. 
5. Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate CA. Measuring geographic atrophy in 
advanced age- related macular degeneration. Investigative ophthalmology & visual science. 
1999;40(8):1761-1769. 
6. Sunness JS, Gonzalez-Baron J, Applegate CA, et al. Enlargement of atrophy and visual acuity 
loss in the geographic atrophy form of age- related macular degeneration. Ophthalmology. 
1999;106(9):1768-1779. 
7. Crabb JW, Miyagi M, Gu X, et al. Drusen p roteome analysis: an approach to the etiology of age-
related macular degeneration. Proceedings of the National Academy of Sciences of the United 
States of America. 2002;99(23):14682-14687. 
8. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in t he complement 
regulatory gene factor H (HF1/CFH) predisposes individuals to age -related macular degeneration. 
Proceedings of the National Academy of Sciences of the United States of America. 
2005;102(20):7227-7232. 
9. Lommatzsch A, Hermans P, Muller KD, Bornfeld N, Bird AC, Pauleikhoff D. Are low 
inflammatory reactions involved in exudative age -related macular degeneration? Morphological 
and immunhistochemical analysis of AMD associated with basal deposits. Graefe's archive for 
clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und 
experimentelle Ophthalmologie. 2008;246(6):803-810. 
10. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-
related macular degeneration contain proteins common to extracellular deposits associated with 
atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology. 2000;14(7):835-
846. 
11. Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H 
polymorphism and age -related macular degeneration. Science. 2005;308(5720):421-424. 
12. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-
related macular degeneration. Science. 2005;308(5720):419-421. 
 
 
Apellis Pharmaceuticals, Inc
Page 68 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
13. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age- related macular 
degeneration. Science. 2005;308(5720):385-389. 
14. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding 
variant in CFH, strongly influences risk of age- related macular degeneration. Nature genetics. 
2006;38(9):1055-1059. 
15. Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk 
of advanced age-related macular degeneration. Nature genetics. 2013;45(11):1366-1370. 
16. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age- related macular 
degeneration. The New Eng land journal of medicine. 2007;357(6):553-561. 
17. van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk 
of age -related macular degeneration. Nature genetics. 2013;45(7):813-817. 
18. Fritsche LG, Chen W, Schu M, et al. Seven new loci associated with age- related macular 
degeneration. Nature genetics. 2013;45(4):433-439, 439e431-432. 
19. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 
(C2) genes is associated with age- related macular  degeneration. Nature genetics. 2006;38(4):458-
462. 
20. Horie -Inoue K, Inoue S. Genomic aspects of age-related macular degeneration. Biochemical and 
biophysical research communications. 2014;452(2):263-275. 
21. Hecker LA, Edwards AO. Genetic control of complement activation in humans and age related 
macular degeneration. Advances in experimental medicine and biology. 2010;703:49-62. 
22. Hecker LA, Edwards AO, Ryu E, et al. Genetic control of the alternative pathway of complement 
in humans and age- related macular degeneration. Human molecular genetics. 2010;19(1):209-
215. 
23. Machalinska A, Dziedziejko V, Mozolewska- Piotrowska K, Karczewicz D, Wiszniewska B, 
Machalinski B. Elevated plasma levels of C3a complement compound in the exudative form of 
age-related macular degeneration. Ophthalmic research. 2009;42(1):54-59. 
24. Scholl HP, Charbel Issa P, Walier M, et al. Systemic complement activation in age -related 
macular degeneration. PloS one. 2008;3(7):e2593. 
25. Leeds JM, Henry SP, Bistner S, Scherrill  S, Williams K, Levin AA. Pharmacokinetics of an 
antisense oligonucleotide injected intravitreally in monkeys. Drug metabolism and disposition: 
the biological fate of chemicals. 1998;26(7):670-675.  
26. Fleckenstein M, Mitchell P, Freund K.B. et al. T he Progression of Geographic Atrophy 
Secondary to Age -Related Macular Degeneration. Ophthalmology . 2018; 125(3):369-390.
 
 
Apellis Pharmaceuticals, Inc
Page 69 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX A: VISIT SCHEDULE —Monthly Group —Screening, Day  1 Through Month 12 (Continued)  
Abbreviations: AH50 = alternative pathway of complement functional test; BCVA = best corrected visual acuity; CH50  = classical pathway of complement functional test; 
CNV = choroidal neovascularization; DCFP  = digital color fundus photography; eCRF = electr onic case report form; FAF = fundus autofluorescence; FFA  = fundus fluorescein 
angiography; FRI  = Functional Reading Independence Index; IOP  = intraocular pressure; LL -BCVA = low luminance best corrected visual acuity;  MNREAD = Minnesota Low -
Vision Reading Test;  NEI VFG -25 = National Eye Institute Visual Functioning Questionnaire 25-Item Version; NIR  = near infrared reflectance; OCT -A = optical coherence 
tomography angiography; PK  = pharmacokinetics; SD -OCT  = spectral domain optical coherence tomography; SE = study eye; Term = termination ; VEGF  = vascular endothelial 
growth factor . 
Note: All ocular assessments are to be performed for both eyes unless annotated with 'SE' (study eye) in the above schedule . All assessments should be performed on the same day.  
All study visits should be scheduled and projected based on the Day 1 visit date with the exception of Visit 2a which should be based on the Day 1 dose date.  
A. For subjects that discontinue the study early, the early termination assessments should be performed after a minimum of 30 days have passed from the last dosing visit. If a 
subject reports for a scheduled visit and decides to terminate early prior to dosing,  the visit should be considered the early termination visit and all early termination proced ures 
should be performed. At Month 24, all subjects should be offered entry into an open-label study.  
B. At Day  1 (Visit  2), confirm subject eligibility through reviewing the inclusion/ exclusion criteria and receive confirmation of eligibility from the reading center . 
C. Significant medical /surgical history from the previous 5 years. Anti-VEGF treatments (fellow eye) and i nvasive ocular procedures performed within the past 5 years and while 
on study should also be recorded. Any history of tobacco use should be recorded.  
D. Obtain prior to fluorescein angiography and before study drug administration.  
E. At screening, serum pregnancy should be performed for women of childbearing potential. If positive, subject is not eligible to continue in the study.  
F. Beginning at Day 1 , perform the urine pregnancy test for women of childbearing potential at each treatment visit. If positive, perform a serum pregnancy test. If serum test is 
positi ve, study drug should not be administered and an early term visit should be completed.  
G. Only subjects that sign the separate consent for the clinical repository  and genotyping will have these samples collected. A 14-mL whole -blood sample will be collected at each 
of the specified visits . 
H. Blood pressure, respiratory rate, heart rate, and temperature.  On dosing days, vital signs should be taken predose.  
I. Height and weight  should be collected  at screening.  
J. Perform assessm ents prior to dilating the eyes.  
K. In select countries , the MNREAD or Radner Reading  Charts should be done during the study visit, prior to dilating the eyes. It should be performed monocularly first, then 
binocularly.  
L. To be administered by the masked site staff prior to any other assessments performed on that day.  In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes.  
M. At select site s, and for those subjects who decide to participate, the digital application s will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the use of the digital applications and the electronic device and will perform the tests using the application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24 . Beginning at Day 1, subjects will complete the functional assessments weekly at 
home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible .  
N. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center  for evaluation (consult the reading center  manual for speci fics on 
image capture, processing, and transmission). Images should be captured prior to dosing on dosing days. If a subject misses a  study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the  next scheduled visit. If new active CNV is suspected, SD-OCT , FFA, and OCT -A (select sites) images 
must be collected and sent to the reading center  for analysis.  
O. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable). If subject passes gross vision test, the subject may leave the site. If subje ct fails gross vision test, the tonometry 
should be performed. IOP should be ≤30  mm Hg in order for the subject to leave the site. If necessary, anti glaucomatous  medication can be given to lower the IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 30  minutes from t he previous measurement until the subject passes gross vision test and IOP is ≤ 30 mm Hg. Note: if 
the study eye is treated with a ranibizumab  or aflibercept  injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept must be performed first. The  pre- and  post- anti-VEGF IOP value s must be measured and recorded on the eCRF.   
 
 
Apellis Pharmaceuticals, Inc
Page 72 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX A: VISIT SCHEDULE —Monthly Group —Screening, Day  1 Through Month 12 (Continued)  
P. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 3) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye. If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
Q. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 da ys of screening and throughout the subject's participation in 
the study.  
R. In addition to  the time points indicated on the study schedule,  OCT -A should be performed at the time of any suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
S. At select sites only.  
T. Administration of study treatment ( pegcetacoplan  or sham ) can be done on a separate day from the assessment visit if both days fall within the visit window. If 
this occurs on the randomization visit, then the administration of pegcetacoplan  or sham  should be done within 3 days of randomization and after approval from 
the medical monitor. When study treatment administration is on a day other than a study visit,  then the only assessment that must be done on the day of study 
treatment administration is the pre injection  IOP. 
  
 
 
Apellis Pharmaceuticals, Inc
Page 73 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX B: VISIT SCHEDULE —Monthly Group —Month 13 to Month 24 (Continued)  
C. Significant medical /surgical history from the previous 5 years. Anti-VEGF treatments (fellow eye) and invasive ocular procedures performed within the past 5  years and while 
on study should also be recorde d. Any history of tobacco use should be recorded.  
D. Obtain prior to fluorescein angiography and before study drug administration.  
E. At screening, serum pregnancy should be performed for women of childbearing potential. If positive, subject is not eligible to continue in the study.  
F. Beginning at Day 1, perform the urine pregnancy test for women of childbearing potential at each treatment visit. If positive, perform a serum pregnancy test. If serum test is 
positive, study drug should not be administered and an early term visit should be completed.  
G. Only subjects that sign the separate consent for the clinical  repository and genotyping will have these samples collected. A 14 -mL whole -blood sample will be collected at each 
of the specified visits.  
H. Blood pressure, respiratory rate, heart rate, and temperature. On dosing days, vital signs should be taken predos e. 
I. Height and weight  should be measured at screening.   
J. Perform assessments prior to dilating the eyes.  
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating the eyes. It should be performed monocularl y first, then 
binocularly.  
L. To be administered by the masked site staff prior to any other assessments performed on that day.  In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes.  
M. At select sites, and for those subjects who decide to participate, the digital applicati ons will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the use of the digital applications and the electronic device and will perform the tests using t he application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24 . Beginning at Day  1, subjects will complete the functional assessments weekly at 
home. Subjects should be instructed to complete the assessments on the sam e day each week and at approximately the same time of day each week, if possible.  
N. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center  for evaluation (consult the reading center  manual for specifics on 
image capture, processing, and transmission). Images should be captured prior to dosing on dosing days. If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit. If new active CNV is suspe cted, SD -OCT, F FA, and OCT -A (selected sites) 
images should be collected and sent to the reading center  for analysis.  
O. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger-
counting, hand motion, then light perception when applicable). If subject passes gross vision test, the subject may leave the site. If subje ct fails gross vision test, the tonometry 
should be performed. IOP should be ≤30  mm Hg in order for the subject to leave the site. If necessary, anti glaucomatous  medication can be given to lower the IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 30  minutes from the previous measurement until the subject passes gross  vision test and IOP is ≤30  mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept must be performed first. Th e pre- and  post - anti-VEGF IOP values must be measured and recorded on the eCRF.  
P. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 3) to collect any information on  any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye. If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
Q. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study.  
R. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV. If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye.  
S. At select sites only.  
T. Administration of study treatment (pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within  the visit window. If this occurs on 
the randomization visit, then the administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the medical monitor. When 
study treatment administration is on a day other than a study visit, then the only assessment that must be done on the day of study treatment administration is the pre injection  
IOP. 
 
 
Apellis Pharmaceuticals, Inc
Page 76 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX C: VISIT SCHEDULE —Every -Other-Month Group —Screening, Day  1 Through Month  12 
(Continued)  
B. At Day  1 (Visit  2), confirm subject eligibility through reviewing the inclusion/ exclusion  criteria and receive confirmation of eligibility from the reading center . 
C. Significant medical /surgical history from the previous 5 years. Anti -VEGF treatments (fellow eye) and invasive ocular procedures performed within the past 5  years and while 
on study should also be recorded. Any history of tobacco use should be recorded.  
D. Obtain prior to fluorescein angiography and before study drug administration.  
E. At screening, serum pregnancy should be performed for women of childbearing potential. If positive, subject is not eligible to continue in the study.  
F. Beginning at Day 1, perform the urine pregnancy test for women of childbearing potential at each treatment visit. If positive, perform a serum pregnancy test. If serum test is 
positive, study drug should not be administered and an early term visit should be completed.  
G. Only subjects that sign the separate consent for the clinical  repository and genotypi ng will have these samples collected. A 14 -mL whole -blood sample will be collected each of 
the specified visits.  
H. Blood pressure, respiratory rate, heart rate, and temperature. On dosing days, vital signs should be taken predose.  
I. Height and weight  should be measured at screening.  
J. Perform assessments prior to dilating the eyes.  
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating the eyes. It should be performed monocularl y first, then 
binocularly.  
L. To be administered by the masked site staff prior to any other assessments performed on that day.  In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures  prior to dilating the eyes.  
M. At select sites, and for those subjects who decide to participate, the digital application will be completed on an electro nic device and will consist of assessments for visual 
function and reading speed. Subjects will receiv e training at Day 1 on the use of the digital applications and the electronic device and will perform the tests using the application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24 . Beginning at Day  1, subjects will c omplete the functional assessments weekly at 
home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible .  
N. FAF and SD -OCT images, near infrared reflectance, f luorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center  for evaluation (consult the reading center  manual for specifics on 
image capture, processing, and transmission). Images should be captured prior to dosing on dosing days. If a subject misses a  study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit. If new active CNV is suspected, SD -OCT, F FA, and OCT -A (select sites) images 
should be collected and sent to the reading center  for analysis.  
O. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable). If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry 
should be performed. IOP should be ≤30  mm Hg in order for the subject to leave the site. If necessary, anti glaucomatous  medication can be given to lower the IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 30  minutes from the previous measurement until the subject passes gross vision test and IOP is ≤30  mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept must be performed first. The pre- and post - anti-VEGF IOP values must be measured and recorded on the eCRF.  
P. Starting at Day  1, study subjects will be contacted by study site staff within 4  ± 2 days after each study treatment visit (through Month 4) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye. If the physician determines that there are any  safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
Q. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in  
the study.  
R. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV. If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye.  
S. At select  sites only.  
 
 
Apellis Pharmaceuticals, Inc
Page 79 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX C: VISIT SCHEDULE —Every -Other-Month Group —Screening, Day  1 Through Month  12 
(Continued)  
T. Administration of study treatment (pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window. If this occurs on 
the randomization visit, then the administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the medical monitor. When 
study treatment administration is on a day other than a study visit, then the only assessment that must be done on the day of study treatment  administration is the pre injection  
IOP.
 
 
Apellis Pharmaceuticals, Inc
Page 80 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX D: VISIT SCHEDULE —Every -Other-Month Group —Month 13 to Month 24 (Continued)  
B. At Day  1 (Visit  2), confirm subject eligibility through revie wing the inclusion /exclusion criteria and receive confirmation of eligibility from the reading center . 
C. Significant medical /surgical history from the previous 5 years. Anti -VEGF treatments (fellow eye) and invasive ocular procedures performed within the past 5  years and while 
on study should also be recorded. Any history of tobacco use should be recorded.  
D. Obtain prior to fluorescein angiography and before study drug administration.  
E. At screening, serum pregnancy should be performed for women of childbearing potential. If positive, subject is not eligible to continue in the study.  
F. Beginning at Day 1, perform the urine pregnancy test for women of childbearing potential at each treatment visit. If positive, perform a serum pregnancy test. If serum test is 
positive, study drug should not be administered and an early term visit should be completed.  
G. Only subjects that sign the separate consent for the clinical repository and genotypi ng will have these samples collected. A 14 -mL whole -blood sample will be collected at each 
of the specified visits.  
H. Blood pressure, respiratory rate, heart rate, and temperature. On dosing days, vital signs should be taken predose.  
I. Height and weight  should be measured at screening.  
J. Perform assessments prior to dilating the eyes.  
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating the eyes. It should be performed monocularl y first, th en 
binocularly.  
L. To be administered by the masked site staff prior to any other assessments performed on that day.  In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes.  
M. At select sites , and for those subjects who decide to participate, the digital applications will be completed on an electronic device and will  consist of assessments for visual 
function and reading speed. Subjects will receiv e training at Day 1 on the use of the digital applications and the electronic device and will perform the tests using the application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24 . Beginning at Day  1, subjects will complete the functional assessments weekly at 
home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible .   
N. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center  for eval uation (consult the reading center  manual for specifics on 
image capture, processing, and transmission). Images should be captured prior to dosing on dosing days. If a subject misses a  study visit or images cannot be obtained at a 
specific visit, study sta ff should make every effort to obtain images at the next scheduled visit. If new active CNV is suspected, SD -OCT, F FA, and OCT -A (select sites) images 
should be collected and sent to the reading center  for analysis.  
O. Postinjection assessments should be performed within 5  minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable). If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry 
should be performed. IOP should be ≤30  mm Hg in order for the subject to leave the site. If necessary, antiglaucomatous medication can be given in order to lower IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 30  minutes from the previous measurement until the subject passes the gross vision test and IOP is ≤30  mm Hg. 
Note: if the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab 
or aflibercept must be performed first. The pre - and  post - anti-VEGF IOP values must be measured and recorded on the eCRF.  
P. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 4) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye. If the investigator  determines that there are any safety 
concerns, a follow -up visit should be scheduled as soon as possible.  
Q. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study.  
R. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV. If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye.  
S. At select  sites only . 
T. Administration of  study treatment ( pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window. If this occurs on 
the randomization visit, then the administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approva l from the medical monitor. When 
study treatment administration is on a day other than a study visit, then the only assessment that must be done on the day of  study treatment administration is the pre injection  
IOP. 
 
 
Apellis Pharmaceuticals, Inc
Page 83 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX E: NATIONAL EYE INSTITUTE VISUAL FUNCTIONING 
QUESTIONNAIRE 25- ITEM VERSION  
  
 
 
Apellis Pharmaceuticals, Inc
Page 84 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 85 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 86 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 87 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 88 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
 
Apellis Pharmaceuticals, Inc
Page 89 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 90 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 91 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 92 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 93 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 94 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 95 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 96 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 97 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 98 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 99 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 100 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX F: FUNCTIONAL READING INDEPENDENCE INDEX  
Kimel M, Yu R, Leidy N. The Functional Reading Independence Index (FRI Index) - User 
Manual (Version 1.2). Evidera. 2015  
  
 
 
Apellis Pharmaceuticals, Inc
Page 101 of 167
Confidential
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 103 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 104 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 105 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 106 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 107 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 108 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 109 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 110 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 111 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 112 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 113 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 114 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 115 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 116 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 117 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 118 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 119 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 120 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 121 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 123 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 124 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 125 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 126 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 127 of 167
Confidential
CCI
  
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 128 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 129 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 130 of 167
Confidential
CCI
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 131 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 132 of 167
Confidential
CCI
 
Pegaetacoplan 
APL2-303 Protocol Amendment 5
 
12 August 2020
 
 
Apellis Pharmaceuticals, Inc
Page 133 of 167
Confidential
CCI
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX G: MINNESOTA LOW-VISION READING TEST AND 
RADNER READING CARDS      
The manual of procedures should be referenced  for a detailed t able of countries and languages to 
determine which test will be administered. Equipment and testing procedures will also be 
described in detail in the manual of procedures for both tests.  
MINNESOTA LOW -VISION READING TEST:  
The Minnesota Low-Vision Reading Test (MNREAD) acuity cards  are continuous -text reading -
acuity cards used for measuring the reading acuity and speed of normal and low-vision patients. These charts were developed at the Minnesota Laboratory for Low -Vision R esearch, University 
of Minnesota, Minneapolis, Minnesota, USA.  
The MNREAD Acuity Charts will be used to measure:  
• Critical print size: the smallest print that the patient can read with maximum speed  
• Maximum reading speed : the patient’s reading speed when reading is not limited by 
print size  
RADNER READING CARDS:  
The Radner Reading Cards consist of sentence optotypes, which are optimized reading test 
items, standardized by construction and statistical selection. These cards allow for accurate and 
comparable measurements of reading acuity and reading speed and measurement of critical print size. 
  
 
 
Apellis Pharmaceuticals, Inc
Page 134 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX H: GRADING SCALE FOR ASSESSMENT  OF ANTERIOR 
CHAMBER FLARE OR CELLS  
AQUEOUS REACTION- FLARE  
Grade  Description  
0 No protein is visible in the anterior chamber when viewed by an experienced observer using 
slitlamp  biomicroscopy; a small, bright, focal slit- beam of white light; and high magnification.  
Trace Trace amount of protein detectable in the anterior chamber. This protein is visible only with careful scrutiny by an experienced observer using slitlamp  biomicr oscopy; a small, bright, focal slit- beam 
of white light; and high magnification.  
1+ Mild amount of protein detectable in the anterior chamber. This protein is immediately apparent to an experienced observer using slitlamp  biomicroscopy and high magnification, but such protein is 
detected only with careful observation with the naked eye an d a small, bright, focal slit- beam of 
white light. Note presence of any fibrin.  
2-3+ Moderate amount of protein detectable in the anterior chamber. These grades are similar to 1+ but the opacity would be readily visible to the naked eye of an observer using any source of a focused beam of white light. This is a continuum of moderate opacification, with 2+ being less apparent than 3+. Note presence of any fibrin.  
4+ A large (severe) amount of protein is detectable in the anterior chamber. Similar to 3+, but the density of the protein approaches that of the lens. Additionally, frank fibrin deposition is frequently seen in acute circumstances. It needs to be noted that because fibrin may persist for a period of time after partial or complete restoration of th e blood- aqueous barrier, it is possible to have resorbing 
fibrin present with lower numeric assignations for flare (e g, 1+ flare with fibrin).  
 
AQUEOUS REACTION- CELLS  
Grade  Description  
0 No cells are seen in any optical section when a large slitlamp  beam is swept across the anterior 
chamber.  
Trace Rare (1 -3) cells are observed when the slitlamp  beam is swept across the anterior chamber. When 
the instrument is held stationary, not every optical section contains circulating cells.  
1+ 3-10 cells/optical section are seen when the slitlamp  beam is swept across the anterior chamber. 
When the instrument is held stationary, every optical section contains circulating cells. Note stage of hypopyon, if applicable.  
2+ 10-25 cells are seen when the slitlamp  beam is swept across the anterior chamber. When the 
instrument is held stationary, every optical section contains circulating cells. Note stage of hypopyon, if applicable.  
3+ 25-50 cells are seen when the slitlamp  beam is swept across the anterior chamber. When the 
instrument is held stationary, every optical section contains circulating cells. Keratic precipitates or cellular deposits on the anterior lens capsule may be present. Note stage of hypopyon, if applicable.  
4+ More than 50 cells are seen when the slitlamp  beam is swept across the anterior chamber. When the 
instrument is held stationary, every optical section contains circulating cells or hypopyon is noted. As for the fibrin deposition, hypopyon may persist for a period of time after exudation of cells into the anterior chamber has diminished or ceased entirely, making it possible for have 1+ circulating cells in the anterior chamber with a resolving hypopyon.  
 
 
Apellis Pharmaceuticals, Inc
Page 135 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX I: GRADING SCALE FOR ASSESSMENT OF VITREOUS 
CELLS  
Grade  Description  Cells in Retro -Illuminated Field  
0 Clear  0 
Trace  Few opacities  1-20 
1 Scattered opacities  21-50 
2 Moderate opacities  51-100 
3 Many opacities  101-250 
4 Dense opacities  ≥251  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page 136 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Section revis
ed to further define approved methods of contraception 
include:  
1. Combined (estrogen -and progestogen -containing) hormonal 
contraception associated with inhibition of ovulation:  
1. Oral  
2. Intravaginal  
3. Transdermal  
2. Progestogen -only hormonal contraception associated with 
inhibition of ovulation:  
1. Oral  
2. Injectable  
3. Implantable  
3. Intrauterine device (IUD)  
4. Intrauterine hormone -releasing system (IUS)  
5. Bilateral tubal occlusion  
6. Vasectomized partner (provided that par tner is the sole sexual 
partner of the WOCBP trial participant and that the 
vasectomized partner has received medical assessment of the 
surgical success)  
7. Sexual abstinence (defined as refraining from heterosexual 
intercourse during the entire period of ris k associated with the 
study treatments). Sexual abstinence is only accepted when it 
is the preferred and usual lifestyle of the subject.  
 
Approved methods of contraception include: oral contraceptives, 
intrauterine device, medically acceptable barrier meth ods (diaphragm 
or condom), implantable or injectable contraceptives (like DepoProvera) 
or removable birth control device (like NuvaRing or Ortho Evra patches); 
and/or surgical sterilization (at least 6 months before dosing). Subjects 
practicing abstinence and coitus interruptus (pull out method) must 
agree to use an approved method of contraception during the study and 
90 days after their last dose of study drug.  
 Section  6.4  Approved Methods of 
Contraception  
The following section was added:  
 
A subject may withdraw from the study at any time for any reason 
without prejudice to his/her future medical care by the physician or at 
the institution . The investigator or sponsor may withdraw the subject at 
any time ( n, in the interest of subject safety) . The investigator is 
encouraged to discuss withdrawal of a subject from treatment with the 
investigational product with the m edical monitor when possible.  
Subjects who discontinue treatment with the investigational product 
can continue participation in the study and should be encouraged  to 
return to the clinical site for as many follow -up visits as they can. In the 
event that a subject terminates early from the study, all early 
termination procedures should be performed even if they are outside 
the allowed study window.  
The reason for termination, date of stopping treatment with Section  6.5  Discontinuation of 
Subjects  
 
 
Apellis Pharmaceuticals, Inc
Page 138 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
investigational product, all follow -up information and the total amount 
of investigational product administered must be recorded in the case 
report form (CRF) and source documents.  
 
 
The requirement to notify the sponsor prior to unmasking was 
removed:  
 
In the event of a medical emergency where the knowledge of subject treatment by masked individuals (eg, the subject or his/her physician) is 
required, an individual Investigator (or designee) will have the ability to unmask the treatment assignment for a specific subject and share that informat ion with the appropriate parties . The Investigator (or designee) 
must endeavor to notify the Sponsor prior to unmasking a subject .  Section  7.2.1  Unmasking  
Section was revised to allow study treatment administration to occur on 
a day separate from the assessment visit:  
 
Only qualified study staff and those delegated the responsibility of study 
drug administration on the Delegation of Authority log should perform this procedure. All staff should be appropriately trained on all 
procedures prior to perform ing the procedures. Sites should follow the 
Visit Schedule for order of procedures and assessments.  
Administration of study treatment (APL -2 or Sham) can be done on a 
separate day from the assessment visit if both days fall within the visit 
window. If thi s occurs on the randomization visit, then the 
administration of APL -2 or Sham should be done within 3 days of 
randomization and after approval from the m edical monitor. When 
study treatment administration is on a day other than  a study visit, 
then the only assessment that must be done on the day of study 
treatment administration is the pre -injection IOP.  
If a subject falls outside the visit window for a dosing visit, the dose should be skipped and the subject should be scheduled on time for the next dosing visit .  Section  7.3.2  Treatment 
Administration  
The description of sham injection was modified as there is no 
requirement for sham to be sterile:  
 
Sham will be provided as sterile  empty stoppered glass vials and should 
be stored according to the label.  
 Section  7.3.3.1 Identity of the 
Investigational Product  
The procedure for sham injection was further described:  
 
The procedure for sham injection will be the same as that used for IVT 
injection until the actual injection but no actual injection will occur . The 
injecting physician will only touch the study eye with the blunt end of 
the syringe. No needle or medication will be injected inside the eye.  Section  7.4  Sham Injection 
Administration  
 
 
Apellis Pharmaceuticals, Inc
Page 139 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
Detailed instructions on sham injection procedures and post -injection 
procedures will be provided in th e manual of procedures.  
The end of the trial for each subject was defined:  
 
The end of the trial for each subject is defined as when the subject 
either completes their Month 24 Visit and enrolls in the open -label 
extension study or, should a subject elect not to enter the open label 
extension study, when the subject completes their exit visit at Month 
30. 
 
Through the section it has also been noted that endothelial cell count assessment is for “select si tes only”. This was previously noted in the 
schedule of events but not consistently in the body of the protocol. In 
addition FAF and NAR are no longer “study eye only”.  Section  8. Study Procedures  
The following assessments were removed as they will no lon ger be 
conducted at the screening Visit  1: 
1. Low luminance BCVA  
2. Endothelial cell count  
3. OCT A 
The following text was moved to Section  8.1.2 as training for home -
based digital applications will now be conducted at Visit  2: 
Prior to dilating the eyes, subjects at select sites will be trained on how 
to use the home based digital applications for visual function and 
reading speed if the subject decides to participate in this portion. This 
training must occur after completion of all functional tests (NL BCVA, LL
BCVA).  Section  8.1.1  Visit  1 All Subjects  
It was clarified that:  
All assessments should be performed on the same day. All study visits 
should be scheduled and projected based on the Day 1 visit date with 
the exception of Visit  2a which should be based on the Day  1 dose date.  
 
The following text was added as home- based digital application training 
will now occur at Visit  2: 
Subjects at select sites will be trained on how to use the home -based 
digital applications for visual function and reading spee d if the subject 
decides to participate in this portion. This training must occur after 
completion of all functional tests (NL -BCVA, LL -BCVA).  
 The following assessments were added:  
4. Endothelial cell count  
5. OCT-A (select sites)  
 
In addition FAF and NAR are no longer “study eye only”.  
 
The following text was removed as subject discontinuation is now covered in Section  6.5. 
In the event that a subject is early terminated from the study, all early 
termination procedures should be performed even if they are outside 
the allowed study window.  Section  8.1.2 Randomization/Initial 
Treatment – Day – Within 28 Days 
of Screening  
 
 
Apellis Pharmaceuticals, Inc
Page 140 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
If the subject would like to discontinue dosing but is amenable to 
continuing in the st udy, the site should make every effort to have the 
subject complete as many follow up visits as possible .  
 
Visit  2A for PK, complement profile (select sites) and Anti -APL-2 
antibody sample collection was added.  
 
Visit  2A- All Groups (select sites)  
Blood should be drawn for PK and Complement profiling (select sites).  Section  8.1.3  PK and Complement 
Sample Day  7 (select sites)  
It has been noted in the text which assessments will be conducted at 
Month 27 and Month 30.  Section  8.1.5 Follow -up Phase  
Blood draw was modified to reflect revised PK sampling schedule.  Table  3 
Instructions were revised to include the following:  
 
All AEs encountered during the study will be monitored and reported in 
detail in the source documents and documented on the eCRF, from 
signing of the ICF until the Exit Visit. AEs should be recorded by 
maximum severity.  AEs, especially those for which the relationship to 
test drug  study treatment are considered by the Investigator to be 
possibly or definitely  related, should be followed up until they have 
returned to the baseline status or stabilized. If a clear explanation is 
established, it should be recorded on the eCRF.  Section  11.2  Recording Adverse 
Events  
Instructions modified as follows:  
If any AEs are serious, special procedures will be followed. All SAEs will 
be reported to the Safety Monitor by the Investigator via fax or email 
within one calendar day of becoming aware of the event, whether or 
not the serious events are deemed drug related. SAE reporting contact 
information will be provided separately and as included in the Safety 
Monitoring Plan. All SAEs must be reported to the applicable  ethics 
committee by the Investigator in accordance with their regulations.  
 
Special procedures will be followed for reporting SAEs. All SAEs will be 
reported to the Safety Monitor by the Investigator via eCRF or fax/email 
(if eCRF is not available)  within 24 hours  of becoming aware of the 
event, whether or not the event is deemed treatment -related. If the 
EDC system is not operational , the site must complete the appropriate 
paper SAE form and fax/email to the number listed on the SAE form, 
also within 24 hours of becoming aware of the event. The reported 
information submitted as a paper SAE form must be entered into the 
EDC system once it becomes operational.  
SAE reporting contact information will be provided separately and 
included in the Safety Monitoring Plan. All SAEs must be reported to the 
applicable ethics committee by the Investigator in accordance with their 
regulations.  Sectio n 11.5 Serious Adverse Events  
The following text was added:  
A suspected adverse reaction means any AE for which there is a 
reasonable possibility that the drug caused the AE. Reasonable Section  11.6 Unexpected Adverse 
Events or Unexpected Suspected Adverse Reactions  
 
 
Apellis Pharmaceuticals, Inc
Page 141 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
half-lives of the active ingredient  (whichever is longer) prior to the start 
of study treatment. Note: clinical trials solely involving observation, 
over -the-counter vitamins, supplements, or diets are not exclusionary.  
The following exclusion criteria was implemented as Exclusion Criteria 
#12 (EC criteria following this were renumbered):  
12. Prior participation in another interventional clinical study for 
geographic atrophy in either eye including investigational oral 
medication and placebo.  Synopsis  
Section  6.1.2 Exclusion Criteria  
Clarified that the following endpoint will not be limited to select sites 
only:   
Change from baseline at each planned assessment in the total area of GA lesion(s) in the study eye (in mm
2) as assessed by FAF.  Synopsis  
Section  12.7.2 Secondary Efficacy 
Endpoints  
Noted that the NEI VFQ -25 distance activity and near activity subscale 
score endpoints will be conducted in select countries  as these subscales 
are not available in all languages.  
 Synopsis  
Section  5.1.3 Secondary Objectives  
Section  5.1.5 Exploratory Objectives  
Section  12.7.2 Secondary Efficacy 
Analysis  
Section  12.7.3 Exploratory Efficacy 
Analysis  
Section  9.9.1 The National Eye 
Institute Visual Functioning 
Questionnaire 25- Item Version (NEI 
VFQ)  
Section  12.7.3 Exploratory Efficacy 
Analysis  
Section  9.9.1 The National Eye 
Institute Visual Functioning Questionnaire 25- Item Version (NEI 
VFQ)  
Contraception text was updated to align with the In vestigator’s 
Brochure and in studies with APL -2 in other indications:  
Approved methods of contraception include: hormonal contraceptives 
associated with inhibition of ovulation,  oral contraceptives,  intrauterine 
device, intrauterine hormone releasing system; and/or bilateral tubal 
occlusion (at least 6 months before dosing)  medically acceptable barrier 
methods (diaphragm or condom), implantable or injectable 
contraceptives (like DepoProvera) or removable birth control device 
(like NuvaRing or Ortho Evra patches); and/or surgical sterilization (at 
least 6 months before dosing).  Subjects practicing abstinence and coitus 
interruptus (pull out method) must agree to use an approved method of contraception during the study and 60 90 days aft er their last dose of 
study drug.  Section  6.4 Approved Methods of 
Contraception  
Masking language was modified to indicate that the PI is required to 
remain masked to subjects’ treatment assignments, while the treating physician and any associated support staff involved in IP administration Section  7.2 Masking and 
Minimization of Bias  
 
 
Apellis Pharmaceuticals, Inc
Page 143 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
will be unmasked.  
Guidance on the treatment of new exudation related to  active choroidal 
neovascularization in the study eye and/or fellow eye was modified to 
clarify that the Reading Center  will provide a report to indicate whether 
or not there is evidence of active, exudative AMD, and the Investigator 
will then determine if anti-VEGF treatment should be initiated. The 
Investigator should wait for the Reading Center  report before making a 
decision regarding treatment, except in cases where there is clear evidence of disease activity that may have a detrimental visual impact i f 
not treated immediately.  
 It was also clarified that either ranibizumab or aflibercept should be 
selected as the anti -VEGF therapy, and that the unmasked physician 
should administer anti -VEGF treatment if the treatment is administered 
on the same day as APL- 2.  
 It was also noted that any treatments of therapies administered to the 
fellow eye within 5  years of screening should be recorded as a 
concomitant medication  
 Section  7.5.1 Treatment of New 
Exudation Related to Active 
Choroidal Neovascularization in the 
Study Eye and/or Fellow Eye  
Visit Schedules A-D  
The following instruction regarding electronic devices was deleted:  
The subject should be instructed to take the electronic device home and 
to complete the digital application weekly on the same day e ach week, 
if possible.  Section  8.1.1 Screening Period  
The following instruction regarding electronic devices was added:  
The subject will be instructed to bring back the electronic device for the 
visits specified in the schedule of events.  Section  8.1.3.1 Months 1 -12 
Month 6 and Month 12 were added as times of in -clinic assessment.  
It was noted that subjects will take electronic devices home at Day  1 
instead of at Screening.  Section  9.12 Home -Based 
Functional Digital Applications (in select sites/countries)  
Visit Schedules A- D. 
Clarified that:  
In the event that a subject is suspected to have new active CNV in the study eye and/or the fellow eye, an SD -OCT and FA using the protocol 
specified procedures should be performed and sent to the Reading 
Center  to confirm the diagnosis. In addition, in select sites, OCT -A 
should also be captured according to the study imaging protocol and 
sent to the Reading Center .  
 Section  9.14 Ocular Imaging  
It was clarified that if the subject does not pass the gross vision test, IOP 
must be measured at that time. Additional IOP measurement must be Section  9.15 Post -Injection 
Assessment; Visit Schedule 
 
 
Apellis Pharmaceuticals, Inc
Page 144 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
therapy.  
Study objectives were expanded to describe the endpoints that will be 
utilized to meet them. Endpoint descriptions were moved to Section  12.  Section  5. STUDY OBJECTIVES AND 
ENDPOINTS  
It was noted that exploratory objectives utilizing digital applications will 
be conducted in select sites/countries only as these applications will be 
utilized according to local regulation. Section  5.1.3 Exp loratory Objectives  
Section  8.1 Study Visit Schedule  
Section  9.13 Home -Based Digital 
Applications (in select 
sites/countries)  
It was clarified that to participate in the study, subjects must be 
diagnosed with GA of the macula secondary to AMD in one or bo th eyes 
the study eye .  
 Section  6. Patient Population  
It was noted that if both eyes have the same visual acuity score, the 
right eye will be selected as the study eye.  Section  6.1.1 Inclusion Criteria  
 
Exclusion criteria 11 was updated as follows:  
11. Prior participation in another interventional clinical study for 
intravitreal therapies in either eye (including subjects receiving sham).  Section  6.1.2 Exclusion Criteria  
Contraception requirements were updated as follows based on 
requiremen ts from ethics committees:  
Approved methods of contraception include: oral  hormonal  
contraceptives associated with inhibition of ovulation , intrauterine 
device, medically acceptable barrier methods (diaphragm or condom), implantable or injectable contraceptives or removable birth control 
device  intrauterine hormone -releasing system; and/or sterilization  
bilateral tubal occlusion  (at least 6 months before dosing) . Subjects 
practicing abstinence and coitus interruptus (pull out method) must 
agree to use an ap proved method of contraception during the study and 
60 days after their last dose of study drug.  
 Section  6.4 Approved Methods of 
Contraception  
“Endothelial cell count” was removed as an assessment that will be 
provided to the Reading Center  for objective assessment of subject 
eligibility.  
 
“Optical Coherence Tomography Angiography (OCT -A, selected sites 
only)” was added as an assessment that will be provided to the Reading 
Center  for objective assessment of subject eligibility.  Section  7.1 Allocation to  Treatment  
Section  8.1. Study Visit Schedule  
“Country” was removed as a stratification factor.  Section  7.1 Allocation to Treatment  
 
 
Apellis Pharmaceuticals, Inc
Page 146 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
References to “DSMB” updated to “DMC”.  Section  7.2.1 Unmasking  
Section  10.1 Data Monitoring 
Committee  
Reference to preparing APL -2 for injection was removed from the 
paragraph describing sham.  Section  7.3.3.1 Identity of the 
Investigational Product  
Text was updated to indicate that:  
The suspected onset or presence of new active choroidal 
neovascularization (CNV) secondary to AMD in the study eye and/or 
fellow eye must be documented in the source document and CRF.  Section  7.5.1 Treatment of New 
Active Choroidal Neovascularization 
in the Study Eye and/or Fellow Eye  
Section  9.15 Ocular Imaging  
Optical Coherence Tomography Angiography (OCT -A) was added as a 
monitoring assessment for select sites to confirm the diagnosis of new active CNV.  Section  7.5.1 Treatment of New 
Active Choroidal N eovascularization 
in the Study Eye and/or Fellow Eye  
Section  9.15 Ocular Imaging  
Text corrected as follows:  
The treatment method (pars plana vitrectomy vs. intravitreal injection 
of antibiotics  vitreous tap) and choice of antimicrobial agents are also at 
the discretion of the physician and should follow current standard practice patterns .  Section  7.5.3 Endophthalmitis 
Treatment  
References to “biobanking” have been replaced by references to the 
“genetic biorepository” and the “clinical repository”.  Section  8. STUDY DESIGN  
Section  9.7 Genotyping Samples  
Section  9.17 Blood Volume for 
Study Assessments  
Noted that blood draws will b e conducted for genotyping.  Section  8.1.3.2 Months 13 -24 
Text was modified to clarify that the study staff performing visual acuity 
should be masked to the treatment assignment only; the protocol previously stated that staff should also be blinded to the study eye.  Section  9.11 Best -corrected Visual 
Acuity and Low Luminance Best -
corrected Visual Acuity  
Blood volume for genetic biorepository was updated.  Section  9.17 Blood Volume for 
Study Assessments  
The following samples were removed:  
a. All residual serum  and whole blood samples collected 
during the course of the study for PK analysis, genotyping and anti -APL- 2 antibody formation  
b. Residual serum PK sample  
c. Residual serum Anti -Therapeutic Antibodies (ATA) sample  Section  9.18.2 Sample Collection  
 
 
Apellis Pharmaceuticals, Inc
Page 147 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
 
It was noted that the 15 mL whole blood sample will be collected at 
Month 2, baseline, Month 12 and Month 24 of the study  
It was clarified that the DMC will meet at the beginning of the study and 
every 6 months thereafter.  Section  10.1 Data Monitoring 
Committee  
Reference to “possibly related” AEs was removed as there is no 
“possibly related” AE categorization for this study.  
 
Resolution outcome possibilities were updated to accurately align with 
the SAE report forms that will be used for this study.  Section  11.2 Recording Adverse 
Events  
 
Section  11.4.1 Relationship of 
Events to Study Treatment  
Clarified that:  
All SAEs will be reported to the Safety Monitor by the Investigator via 
fax or email within one working calendar  day of becoming aware of the 
event, whether or not the serious events are deemed drug -related.  Section  11.5 Serious Adverse Events  
Section reorganized, modified, and updated to depict protocol 
specifications for data management and statistical considerations more 
clearly, accurately, and thoroughly.  Section  12. DATA MANAGEMENT 
AND STATISTICAL CONSIDERATIONS  
Footnote was updated to indicate that: All assessments should be 
performed on the same day, with the exception of screening.  
 
Frequency of microperimetry and endothelial cell count was updated. 
Microperimetry footnote was updated to remove reference to the study 
eye as that assessment will now be conducted on both eyes.  
 
The blood draw for the clinical repository was removed at b aseline, 
Month 1, Month 8, Month 18, and Month 27.  
 OCT-A was added at screening, Month 6, Month 12, Month 18, and 
Month 24 for select sites. Footnote “S” was added to note that in 
addition to the time points indicated on the study schedule, OCT -A 
should be performed at the time of any suspected new active CNV. If new active CNV is confirmed in the study eye, OCT -A should be 
repeated every 2 months for the study eye.  All Study Schedules (Appendices: A, 
B, C, and D)  
 
 
Apellis Pharmaceuticals, Inc
Page 148 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX K: PROTOCOL CHANGES TO BE FOLLOWED DURING 
COVID -19 RESTRICTIONS 
OVERVIEW   
In response to the COVID-19 crisis, to ensure the safety of study subjects and Investigative Sites  
as well as proper conduct of the study, TEMPORARY changes to the protocol have been 
implemented. These cha nges should be followed only during COVID-19 restrictions  and include 
extended IP administration windows, changes to masking rules, rescreening instructions, and a 
revised schedule of assessments.  
Where feasible,  sites could continue to follow the full schedule of assessments (based on their 
treatment group assignment). 
EXTENDED IP ADMINISTRATION WINDOW S 
In order t o allow more flexibility  to sites and subjects, and to potentially mitigate missed IP 
administration, an extended IP administration  window can be followed. Th e extended window  
can ONLY be used in situations related to COVID- 19 restrictions and after medical monitor 
approval. Footnote “T” of each COVID -19 a ssessment table below reflects these extended IP 
options. 
Per protocol, the IP administration  window is as follows: 
• Monthly treatment group: +/– 8 days for the entire study duration 
• EOM treatment group: +/– 8 days for the first study year and +/- 16 days for the 
second study year 
During COVID-19 restrictions, the IP administration  window can be extended to the following: 
• Monthly treatment group: –8 days to +15 days. Note, interval for consecutive injection s must be at least 14 days.  
• EOM treatment group: –8 days to +30 days for the first study year and –16 days to +30 days for the second study year. 
MASKING RULES  
Due to current COVID- 19 restrictions, clinical sites might encounter difficulties maintaining 
appropriate clinic staffing to satisfy the approved masking rules for the APL2-303 (Derby) study. Based on this, and in an attempt to minimize the amount of missed data and IP administrations, Apellis is implementing a  temporary  adjustment to the study masking rules.  
This temporary change must be approved by the Apellis Medical Director prior to  
implementation and must be documented via a temporary and modified delegation of authority 
Log. E ach masked assessment performed by an unmasked staff and vice versa (even with Apellis 
approval and following the below guidelines) should be documented.  
The principal investigator (PI) is responsible for the overall oversight of the study site data and  
s/he will not be allowed to switch into an unmasked role. Every masked individual that performs IP administration  and/or post injection  assessment (all unmasked assessment) as a tempora ry 
measure, will permanently  be considered an unmasked individual and will not be able to 
perform masked assessments once these exemptions are lifted.  
 
 
Apellis Pharmaceuticals, Inc
Page 149 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
RESCREENING PROCEDURE  
Prior to the implementation of these temporary changes, sites continuing to screen patients have 
been encouraged to complete the screening and baseline assessments in their entirety. However, if a subject was deemed a screen failure for not being able to m eet the original screening window 
(Day –28 to Day –1 [+/- 2 days]) due to COVID- 19 related restrictions, a rescreening visit is 
allowed and should be followed according to the 2 scenarios below. 
 
Subjects Who Completed Screening and Were Considered Eligible b y Reading Center and 
Investigator  
Subjects who were screened prior to 30 March  2020 and completed  all screening assessments (as 
described in the Schedule of Assessments Appendix A  [every month treatment group] and 
Appendix C  [every other month [EOM] treatment group]) and considered eligible by the reading 
center  and in vestigator and are able to return to the clinic within 90 days of initial screening, will 
receive a new subject ID number and undergo an abbreviated screening, prior to randomization, 
that includes the following assessments:   
• Informed consent/assign new screening number  
• Normal luminance best corrected visual acuity assessment   
• Slitlamp  examination   
• Dilated indirect ophthalmoscopy  
• IOP measurement   
• SD-OCT*    
• Concomitant medication/concomitant ocular procedures collection  
• AE collection   
*SD- OCT images collected at this visit will not be used by the reading center  to determine 
eligibility but should be used by the investigator to detect any potential new exclusion criterion.  
If the investigator deems it necessary, additional assessments can be performed  if there is a 
concern that the subject might now meet an exclusion criterion that was not the case during the original screening (eg, FFA to exclude the presence of CNV).  
 
Subjects With Incomplete Screening Assessment   
Subjects that signed the informed consent but were not able to complete all screening assessments due to COVID-19- related restrictions  are not eligible for the abbreviated screening. 
These subjects  can be rescreened but  must follow the standard screening schedule of 
assessment  (as described in  the Schedule of Assessments Appendix A  [every month treatment 
group] and Appendix C  [EOM  treatment group]). These subjects will also receive a new 
screening ID number.  
MINIMUM SCHEDULE OF ASSESSMENT  
Schedule of Assessments   
Where feasible,  sites could continue to follow the full schedule of assessments (based on their 
treatment group assignment). The minimum assessment tables,  only to be followed during this 
 
 
Apellis Pharmaceuticals, Inc
Page 150 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
COVID- 19 effort  and if determined necessary to use based on the investigator’s clinical 
judgment, are provided below to reduce the time required for each study visit. Subjects  in the 
EOM treatment group do not need to be seen for the non- IP administration visits. Assessments 
not performed (even those that have been removed in the minimum assessment table) should be 
documented.  
Subjects that are not able to come into the clinic for a study visit due to COVID-19- related 
restrictions, including visits for the EOM group that do not include IP administration, should 
be contacted via the phone for the collection of AEs  (including SAEs) and concomitant 
medications.  All SAEs are still required to be reported to Apellis within 24 hours  of site 
awareness, even if reported via phone call . All communications via phone call should also be 
documented in the source documents and in the respective CRF page. In addition, these 
subjects  should be instructed to self-monitor their vision at home and report any changes in 
vision or their overall health via phone call. The site must inform the Sponsor of any subjects lost to follow-up. 
 
It is critical that local,  country, and regional governance regarding COVID-19 is followed along 
with your best clinical judgment when managing this situation . All visits or assessments missed 
as a result of COVID -19 will be captured in the case report forms . 
The Schedule of Assessments tables shown below supersede those sent on 30 March  2020. These 
changes were previously communicated to the sites via a memorandum.  
 
 
Apellis Pharmaceuticals, Inc
Page 151 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX A (TRACKED): COVID-19 VISIT SCHEDULE —Monthly Group— Screening, Day  1 Through Month 12  
Abbreviations: AH50 = alternative pathway of complement functional test; BCVA  = best corrected visual acuity; CH50  = classical pathway of complement functional test; 
CNV = choroidal neovascularization; DCFP  = digital color fundus photography; eCRF  = electronic case report form; FAF  = fundus autofluorescence; FFA  = fundus fluorescein 
angiography; FRI  = Func tional Reading Independence Index; IOP  = intraocular pressure; LL -BCVA = low luminance best corrected visual acuity; MNREAD  = Minnesota Low -
Vision Reading Test; NEI VFG -25 = National Eye Institute Visual Functioning Questionnaire 25-Item Version; NIR  = near infrared reflectance; OCT -A = optical coherence 
tomography angiography; PK  = pharmacokinetics; SD -OCT  = spectral domain optical coherence tomography; SE  = study eye; Term = termination; VEGF  = vascular endothelial 
growth factor.  
Note: All ocular assessments are to be performed for both eyes unless annotated with 'SE' (study eye) in the above schedule. All assessments should be  performed on the same day. 
All study visits should be scheduled and projected based on the Day 1 visit date with the exception of Visit  2a which should be based on the Day 1 dose date.  
A. For subjects that discontinue the study early, the early termination assessments should be performed after a minimum of 30  days have passed from the last dosing visit. If a 
subject reports for a sch eduled visit and decides to terminate early prior to dosing, the visit should be considered the early termination visit and a ll early termination procedures 
should be performed. At Month 24, all subjects should be offered entry into an open-label study.  
B. At Day  1 (Visit  2), confirm subject eligibility through reviewing the inclusion /exclu sion criteria and receive confirmation of eligibility from the reading center . 
C. Significant medical /surgical history from the previous 5 years. Anti -VEGF treatments ( fellow eye) and invasive ocular procedures performed within the past 5 years and while 
on study should also be recorded. Any history of tobacco use should be recorded.  
D. Obtain prior to fluorescein angiography and before study drug administration.  
E. At s creening, serum pregnancy should be performed for women of childbearing potential. If positive, subject is not eligible to continue in the study.  
F. Beginning at Day 1, perform the urine pregnancy test for women of childbearing potential at each treatment  visit. If positive, perform a serum pregnancy test. If serum test is 
positive, study drug should not be administered and an early term visit should be completed.  
G. Only subjects that sign the separate consent for the clinical repository and genotyping will have these samples collected. A 14 -mL whole -blood sample will be collected at each 
of the specified visits.  
H. Blood pressure, respiratory rate, heart rate, and temperature. On dosing days, vital signs should be taken predose.  
I. Height and weight  shou ld be collected at screening.  
J. Perform assessments prior to dilating the eyes.  
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating the eyes. It should be performed monocularl y first, then 
binocularly.  
L. To be administered by the masked site staff prior to any other assessments performed on that day. In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes.  
M. At select sites, and for those subjects who decide to participate, the digital applicati ons will be completed on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the use of the digital applications and the electronic device and will perform the tests using t he application  
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24. Beginning at Day 1, subjects will complete the functional assessments weekly at 
home. Subjects should be instructed to complete the assessments on the sam e day each week and at approximately the same time of day each week, if possible.  
N. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center  for evaluation (consult the reading center  manual for specifics on 
image capture, processing, and transmission). Images should be captured prior to dosing on dosing days. If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit. If new active CNV is suspe cted, SD -OCT, FFA , and OCT -A (select sites) images 
must be collected and sent to the reading center  for analysis.  
O. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable). If subject passes gross vision test, the subject may leave the site. If subje ct fails gross vision test, the tonometry 
should be performed. IOP should be ≤30  mm Hg in order for the subject to le ave the site. If necessary, anti glaucomatous  medication can be given to lower the IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 30  minutes from the previous measurement until the subject passes gross vision test and IOP is ≤30  mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept must be performed first. The pre- and post - anti-VEGF IOP values must be measured and recorded on the eCRF.  
 
 
Apellis Pharmaceuticals, Inc
Page 154 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX A (TRACKED): COVID-19 VISIT SCHEDULE —Monthly Group— Screening, Day  1 Through Month 12  
P. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 3) to collect any informat ion on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye. If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
Q. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study.  
R. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV. If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye.  
S. At select sites only.  
T. Administration of study treatment (pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window. If this occurs on 
the rando mization visit, then the administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the medical monitor. When 
study treatment administration is on a day other than a study visit, then the only assessment that must be done on the day of study treatment administration is the pre injection  
IOP. During the COVID-19 pandemic, the following flexibility is allowed for IP administration : –8 days to +15 days  after medical monitor approval . Note, interval for 
consecutive injections must be at least 14 days .  
 
 
Apellis Pharmaceuticals, Inc
Page 155 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX B (TRACKED): COVID- 19 VISIT SCHEDULE —Monthly Group—Month 13 to Month 24  
A. For subjects that discontinue the study early, the early termination assessments should be performed after a minimum of 30  days have passed from the last dosing visit. If a 
subject reports for a scheduled visit and decides to terminate early prior to dosing, then the visit should be considered the  early termination visit and all early termination 
procedures should be performed. At Month 24, all subjects should be offered entry into an open-label study.  
B. At Day  1 (Visit  2), confirm subject eligibility through reviewing the inclusion /exclusion criteria and receive confirmation of eligibility from the reading center . 
C. Significant medical /surgical history from the previous 5 years. Anti -VEGF treatments (fellow eye) and invasive ocular procedures performed within the past 5  years and while 
on study should also be recorded. Any history of tobacco use should be recorded.  
D. Obtain prior to fluorescein angiography and before study drug administration.  
E. At screening, serum pregnancy should be performed for women of childbearing potential. If positive, subject is not eligible to continue in the study.  
F. Beginning at Day 1, perform the urine pregnancy test for women of childbearing potential at each treatment visit. If positive, perform a serum pregnancy test. If serum test is 
positive, study drug should not be administered and an early term visit should be completed.  
G. Only subjects that sign the separate consent for the clinical repository and genotypi ng will have these samples collected. A 14 -mL whole -blood sample will be collected at each 
of the specified visits.  
H. Blood pressure, respiratory rate, heart rate, and temperature. On dosing days, vital signs should be taken predose.  
I. Height and weight  should be measured at screening.  
J. Perform assessments prior to dilating the eyes.  
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating the eyes. It should be performed monocularl y first, then 
binocularly.  
L. To be administered by the masked site staff prior to any other assessments performed on that day. In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life mea sures prior to dilating the eyes.  
M. At select sites, and for those subjects who decide to participate, the digital applications will be completed on an electr onic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day1 on the use of the digital applications and the electronic device and will perform the tests using the application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24. Beginning at Day 1, subjects will complete the functional assessments weekly at 
home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible .  
N. FAF and SD -OCT images, near infrared reflectan ce, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center  for evaluation (consult the reading center  manual for specifics on 
image capture, processing, and transmission). Images should be captured prior to dosing on dosing days. If a subject misses a  study visit or images cannot be obtained at a 
specific visit, study staff should m ake every effort to obtain images at the next scheduled visit. If new active CNV is suspected, SD -OCT, FFA, and OCT -A (selected sites) 
images should be collected and sent to the reading center  for analysis.  
O. Postinjection assessments should be performed within 5  minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable). If subject passes gross vision test, the subject may leave the sit e. If subject fails gross vision test, the tonometry 
should be performed. IOP should be ≤30  mm Hg in order for the subject to leave the site. If necessary, anti glaucomatous  medication can be given to lower the IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 30  minutes from the previous measurement until the subject passes gross vision test and IOP is ≤30  mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as t he study treatment ( pegcetacoplan  or sham ), the treatment with ranibizumab or 
aflibercept must be performed first. The pre- and post - anti-VEGF IOP values must be measured and recorded on the eCRF.  
P. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 3) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye. If the physician dete rmines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
Q. Record concomitant medications (i e, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the s ubject's participation in 
the study.  
R. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV. If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye.  
S. At select sites only.  
 
 
Apellis Pharmaceuticals, Inc
Page 158 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX B (TRACKED): COVID- 19 VISIT SCHEDULE —Monthly Group—Month 13 to Month 24  
T. Administration of pegcetacoplan  or sham  can be done on separate days from the assessment visit if both days fall within the visit window. Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window. If this occurs on the ra ndomization visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the medical monitor. When study treatment administration is on 
a day other than a study visit, then the only assessment that must be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: –8 days to +15 days  after medical monitor approval. Note, interval for consecutive injections must be at least 14 days.  
  
 
 
Apellis Pharmaceuticals, Inc
Page 159 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX C (TRACKED): COVID- 19 VISIT SCHEDULE —Every -Other- Month Group—Screening, Day  1 Through   
Month  12 
Note: All ocular assessments are to be performed for both eyes unless annotated with 'SE' (study eye) in the above schedule. All assessments should be performed on the same day. 
All study visits should be scheduled and projected based on the Day 1 visit date with the exception of Visit 2a which should be based on the Day 1  dose date. 
A. For subjects that discontinue the study early, the early termination assessments should be performed after a minimum of 30 days have passed from the last dosing visit. If a 
subject reports for a scheduled visit and decides to terminate early prior to dosing, the visit should be considered the early termination visit and all early termination procedures 
should be performed At Month 24, all subjects should be offered entry into an open-label study.  
B. At Day  1 (Visit  2), confirm subject eligibility thro ugh reviewing the inclusion /exclusion criteria and receive confirmation of eligibility from the reading center . 
C. Significant medical /surgical history from the previous 5 years. Anti -VEGF treatments (fellow eye) and invasive ocular procedures performed within the past 5 years and while 
on study should also be recorded. Any history of tobacco use should be recorded.  
D. Obtain prior to fluorescein angiography and before study drug administration.  
E. At screening, serum pregnancy should be performed for women of childbearing potential. If positive, subject is not eligible to continue in the study.  
F. Beginning at Day 1, perform the urine pregnancy test for women of childbearing potential at each treatment visit. If positive, perform a serum  pregnancy test. If serum test is 
positive, study drug should not be administered and an early term visit should be completed.  
G. Only subjects that sign the separate consent for the clinical  repository and genotyping will have these samples collected. A 1 4-mL whole -blood sample will be collected each of 
the specified visits.  
H. Blood pressure, respiratory rate, heart rate, and temperature. On dosing days, vital signs should be taken predose.  
I. Height and weight  should be measured at screening.  
J. Perform assessments prior to dilating the eyes.  
K. In select countries, the MNREAD or Radner Reading Charts should be done during the study visit, prior to dilating the eyes. It should be performed monocularl y first, then 
binocularly.  
L. To be administered by the masked site staff prior to any other assessments performed on that day. In-clinic assessments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eye s. 
M. At select sites, and for those subjects who decide to participate, the digital application will be completed on an electro nic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the  use of the digital applications and the electronic device and will perform the tests using the application 
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24. Beginning at Day 1, subjects will complete the functional ass essments weekly at 
home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible .  
N. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and  fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center  for evaluation (consult the reading center  manual for specifics on 
image capture, processing, and transmission). Images should be captured prior to dosing on dosing days. If a subject misses a  study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit. If new active CNV is suspected, SD -OCT, FFA, and OCT -A (select sites) images 
should be collected and sent to the reading center  for analysis.  
O. Post - injection assessments should be performed within 5  minutes after dosing b y the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable). If subject passes gross vision test, the subject may leave the site. If subje ct fails gross visio n test, the tonometry 
should be performed. IOP should be ≤30  mm Hg in order for the subject to leave the site. If necessary, anti glaucomatous  medication can be given to lower the IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 30  minutes from the previous measurement until the subject passes gross vision test and IOP is ≤30  mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept must be performed first. The pre- and post - anti-VEGF IOP values must be measured and recorded on the eCRF.  
P. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 da ys after each study treatment visit (through Month 4) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye. If the physician determines that there are any safety  concerns, 
a follow -up visit should be scheduled as soon as possible.  
Q. Record concomitant medications ( ie, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the st udy.  
 
 
Apellis Pharmaceuticals, Inc
Page 162 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX C (TRACKED): COVID- 19 VISIT SCHEDULE —Every -Other- Month Group—Screening, Day  1 Through   
Month  12 
R. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV. If new  active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye.  
S. At select  sites only.  
T. Administration of study treatment (pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window. If this occurs on 
the randomization visit, then the administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approva l from the medical monitor. When 
study treatment administration is on a day other than a study visit, then the only assessment that must be done on the day of  study treatment administration is the pre injection  
IOP. During the COVID -19 pandemic, the followi ng flexibility is allowed for IP administration: –8 days to +30 days  after medical monitor approval .  
  
 
 
Apellis Pharmaceuticals, Inc
Page 163 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX D (TRACKED): COVID- 19 VISIT SCHEDULE —Every -Other- Month Group—Month 13 to Month 24 
A. For subjects that discontinue the study early, the early termination assessments  should be performed after a minimum of 30 days have passed from the last dosing visit. If a 
subject reports for a scheduled visit and decides to terminate early prior to dosing, then the visit should be considered the  early termination visit and all early  termination 
procedures should be performed. At Month 24, all subjects should be offered entry into an open label study.  
B. At Day  1 (Visit  2), confirm subject eligibility through reviewing the inclusion /exclusion criteria and receive confirmation of elig ibility from the reading center . 
C. Significant medical /surgical history from the previous 5 years. Anti -VEGF treatments (fellow eye) and invasive ocular procedures performed within the past 5  years and while 
on study should be recorded. Any history of tobacco use should be recorded.  
D. Obtain prior to fluorescein angiography and before study drug administration.  
E. At screening, serum pregnancy should be performed for women of childbearing potential. If positive, subject is not eligible to continue in the study.  
F. Beginning at Day 1, perform the urine pregnancy test for women of childbearing potential at each treatment visit. If positive, perform a serum  pregnancy test. If serum test is 
positive, study drug should not be administered and an early term visit should be completed.  
G. Only subjects that sign the separate consent for the clinical repository and genotyping will have these samples collected. A 14 -mL whole -blood sample will be collected at the 
specified time points . 
H. Blood pressure, respiratory rate, heart rate, and temperature. On dosing days, vital signs should be taken pre - dose.  
I. Height and weight  should be measured at screening.  
J. Perform assessments prior to dilating the eyes.  
K. In select countries, the MNREAD or Radner Rea ding Charts should be done during the study visit, prior to dilating the eyes. It should be performed monocularly first, then  
binocularly.  
L. To be administered by the masked site staff prior to any other assessments performed on that day. In-clinic assess ments on the digital application should be completed after 
completion of all functional tests and quality of life measures prior to dilating the eyes.  
M. At select sites, and for those subjects who decide to participate, the digital applications will be co mpleted on an electronic device and will consist of assessments for visual 
function and reading speed. Subjects will receive training at Day 1 on the use of the digital applications and the electronic device and will perform the tests using the application  
in the clinic at Month 1, Month 2, Month 3, Month 6, Month 12, Month 18, and Month 24. Beginning at Day 1, subjects will complete the functional assessments weekly at 
home. Subjects should be instructed to complete the assessments on the same day each week and at approximately the same time of day each week, if possible.  
N. FAF and SD -OCT images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center  for evaluation (consult the reading center  manual for specifics on 
image capture, processing, and transmission). Images should be captured prior to dosing on dosing days. If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit. If new active CNV is suspe cted, SD -OCT, FFA, and OCT -A (selected sites) 
images should be collected and sent to the reading center  for analysis.  
O. Postinjection assessments should be performed within 5 minutes after dosing by the unmasked physician or study staff and should include a gross assessment of vision (finger -
counting, hand  motion, then light perception when applicable). If subject passes gross vision test, the subject may leave the site. If subje ct fails gross vision test, the tonometry 
should be performed. IOP should be ≤30  mm Hg in order for the subject to leave the site. If necessary, antiglaucomatous medication can be given in order to lower IOP. If IOP is 
>30 mm Hg, assessments will continue every approximately 30  minutes from the previous measurement until the subject passes the gross vision test and IOP is ≤30  mm Hg. 
Note: if the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab 
or aflibercept must be performed first. The pre - and post - anti-VEGF IOP values must be measured and recorded on the eCRF.  
P. Starting at Day  1, study subjects will be contacted by study site staff within 4 ± 2 days after each study treatment visit (through Month 4) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye. If the investigator determines that there are any safety 
concerns, a follow -up visit should be scheduled as soon as possible.  
Q. Record concomitant medications (i e, prescription and over -the-counter medications) used by the patient within 30 days of screening and throughout the subject's participation in 
the study.  
R. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV. If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye.  
S. At select  sites only.  
 
 
Apellis Pharmaceuticals, Inc
Page 166 of 167
Confidential
Pegcetacoplan  
APL2 -303 Protocol Amendment 5  12 August 2020  
APPENDIX D (TRACKED): COVID-19 VISIT SCHEDULE —Every -Other- Month Group—Month 13 to Month 24 
T. Administration of pegcetacoplan  or sham  can be done on separate days from the assessment visit if both days fall within the visit window. Administration of study tre atment 
(pegcetacoplan  or sham) can  be done on a separate day from the assessment visit if both days fall within the visit window. If this occurs on the randomiz ation visit, then the 
administration of pegcetacoplan  or sham should be done within 3 days of randomization and after approval from the medical monitor. When study treatment administration is on 
a day other than a study visit, then the only assessment that must be done on the day of study treatment administration is pr einjection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: –16 days to +30 days  after medical monitor approval .  
 
 
 
Apellis Pharmaceuticals, Inc
Page 167 of 167
Confidential